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DYNAMIC ASSESSMENT OF NK CELL INTERACTIONS WITH PEDIATRIC 
TUMOR CELLS TO PREDICT RESPONSE TO IMMUNOTHERAPY 
Arianexys Aquino-López, BS 
Advisory Professor: Eugenie S. Kleinerman, MD  
Due to Natural Killer (NK) cells’ capacity to target tumor cells without prior 
sensitization, adoptive NK cell therapy represents a promising immunotherapy 
approach for pediatric cancer patients. Our laboratory has developed an NK cell 
expansion protocol that generates large quantities of NK cells for therapeutic infusion. 
Given that NK cells are heterogeneous, with variable receptor expression and potential 
to target tumor cells, the purpose of my study was to determine whether subpopulations 
of NK cells with enhanced anti-tumor potential could be identified for increased potency 
of the NK cell infusion product. In addition, we previously showed that our expanded NK 
cells secret 20 times more IFNγ than resting NK cells. Opposing effects have been 
reported for IFNγ on tumor sensitivity to NK-mediated lysis. Therefore, another aim of 
my study was to evaluate the effect of IFNγ on tumor sensitivity to NK cell mediated lysis, 
tumor expression of NK cell ligands, and NK:tumor interactions using a standardized 
panel of cell lines corresponding to 6 types of pediatric malignancies.  
My results demonstrate the presence of unique NK cell subpopulations in the 
expanded product that are absent in primary NK cells. These subpopulations co-express 
higher levels of multiple activating receptors than primary NK cells. Moreover, compared 
to the NK cell subpopulations that are common to both primary and expanded NK cells, 
the unique subpopulations showed increased degranulation (CD107a) and IFNγ 
secretion in response to tumor cell encounter.   
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I also demonstrate that IFNγ has a variable impact on NK-mediated lysis of 
pediatric tumor cell lines, with some cell lines becoming more resistant to NK cells and 
others becoming more sensitive. Broad screening of NK cell ligands on these cell lines 
using mass cytometry, and flow cytometry, show that both exogenous and NK cell 
secreted IFNγ cause significant upregulation of PD-L1, ICAM-1, and MHC-class I, but 
this upregulation varies widely between the cell lines. Modeling of the data suggests that 
the effect of IFNγ on NK cell-mediated tumor lysis is mostly dependent on relative 
changes in MHC-class I and ICAM-1 expression. In cell lines with increased sensitivity 
after IFNγ treatment, ICAM-1 upregulation exceeded that of MHC-class I upregulation. 
This ICAM-1 upregulation resulted in increased conjugate formation between the NK 
cells and tumor cells. Timelapse imaging of neurobastoma cells with increased sensitivity 
revealed that IFNγ treatment also decreased the time for NK cell encounter of tumor cells 
(tseek). Blocking of ICAM-1 weakened the increased sensitivity observed after IFNγ 
treatment for selected cell lines and NK donors. Although ICAM-1 and MHC-class I were 
identified as key role players, the effects of MHC-class I and ICAM-1 are not always 
predictable. 
This identification of hyperactive NK cell subpopulations with enhanced IFNγ 
secretion and a better understanding of the impact of IFNγ on NK:tumor interactions 
provides important information that can be used to further improve NK cell 
immunotherapy of cancer. 
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CHAPTER I: INTRODUCTION: BACKGROUND, RATIONALE AND RESEARCH 
PLAN 
Pediatric Cancer: Epidemiology and Current Therapies 
Although pediatric malignancies are considered rare diseases, approximately 1 
of 285 children in the United States (U.S.) will be diagnosed with cancer before 
reaching age 20 (1). Second only to accidents, cancer is a leading cause of death 
for children between the ages of 5-14 years (1). The most common cancer types 
among children and teenagers (0-19 years) are leukemia, brain & CNS tumors, and 
lymphoma. In a prospective study including children diagnosed with cancer between 
1991 and 2000, the 5-year survival rates were 74% for leukemia, 72% for brain & 
CNS tumors, and 87% for lymphoma (1). Although there has been some 
improvements in survival for Acute Lymphoblastic Leukemia (ALL) and Non-
Hodgkin’s Lymphoma, there has been little or no progress for solid tumors including 
rhabdomyosarcoma (RMS), osteosarcoma, Ewing sarcoma (EWS) or gliomas for 
the past 20 years (2). For those children that survive, it is at the expense of 
increased morbidity and complications later in life. According to the Childhood 
Cancer Survivor Study (CCSS), when compared to their healthy siblings, pediatric 
cancer survivors have an increased incidence of long term complications (3, 4). 
Survivors that received chemotherapy or radiation had ~5 times higher risk of 
developing disabling, life threatening or fatal conditions, when compared to their 
siblings (4). Also, by age 50, half of the childhood cancer survivors experience some 
type of cardiovascular, renal, hepatic, pulmonary, and/or gonadal dysfunction (4).  
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One of the most serious late effects of chemotherapy and radiation in cancer 
survivors is the increased risk of developing secondary malignancies (4). For 5-year 
survivors of childhood cancer, secondary malignancies related to treatment are the 
leading cause of premature mortality (5) . Radiation has been associated to 
increased risk of developing secondary solid tumors, while chemotherapy has been 
linked to increased risk of developing secondary hematologic malignancies (5, 6).  
Therefore, there is a need to improve therapeutic options for pediatric cancer 
patients not only to increase survival rates, but also to decrease morbidity 
associated with current therapeutic regimens.  
Cancer Immunotherapies: Natural Killer Cells for Pediatric Cancers 
The immune system protects the body from pathogens including bacteria, 
viruses and parasitic worms. In addition, the immune system provides cancer 
surveillance and serves to eliminate tumor transformed cells (7). Natural Killer (NK) 
cells and macrophages from the innate immune system, as well as T cells and B 
cells from the adaptive immune system, serve to provide anti-tumor responses. 
Cancer immunotherapy uses the immune system components, or agents that modulate 
the immune system, to provide an anti-tumor effect and is a promising tool for the 
treatment of pediatric malignancies (8).  In the recent years multiple immunotherapies 
have been developed for cancer treatment, some of these approaches include 
checkpoint inhibitor antibodies (anti-CTLA4, anti-PD-1/PD-L1), tumor infiltrating 
lymphocytes (TILs), T cells with Chimeric Antigen Receptors (CAR-T cells), adoptive cell 
therapies, among others (8).  
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Immune checkpoints function in our body to regulate T cell activity and avoid 
autoimmune responses. However, some tumor cells use these same inhibitory 
checkpoints (i.e. CTLA-4, and PD-1/PD-L1 axis) to acquire tolerance and evade the 
immune system (8).  Checkpoint inhibitor antibodies block T cell inhibition and allow for 
enhanced T cell activity. However, Cytotoxic T lymphocytes (CTLs) rely on the T cell 
receptor (TCR) recognition of tumor antigens presented in the context of major 
histocompatibility complex (MHC) molecules, therefore the therapeutic efficacy of 
checkpoint inhibitors, in part, relies on an efficient interaction between the TCR and the 
antigen presented in the context of MHC (9).  Similarly other therapies, such as TILs rely 
on the TCR interaction with antigens presented on MHC. In 40-90% of human tumors 
the MHC class I molecules, also known as Human Leukocyte Antigen class I (HLA-class 
I) is downregulated (10, 11). In the pediatric cancer field neuroblastoma and Ewing 
sarcomas, have been reported to have low HLA-A,B,C expression (11). This 
downregulation can affect the efficacy of CTL responses. To overcome this limitation 
CAR T cell therapies have been developed. CAR stands for chimeric antigen receptor, 
and its structure is composed of an antibody in the form of single chain Fv (scFv) as the 
extracellular domain and an intracellular T cell signaling domain. CAR T cells are capable 
of direct antigen recognition and do not require the antigen to be presented in the context 
of MHC. In order for CAR T cells to be safe, and to avoid unwanted effects in healthy 
tissues, the antigen should be expressed preferentially on malignant cells (12, 13). 
Although CAR T cell therapies are capable of overcoming MHC downregulation, their 
efficiency relies on the expression of a known antigen expressed on cancer cells.  CAR 
T cells have shown promise for cancer types with known cancer antigens such as CD19 
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for B-cell acute lymphoblastic leukemia (B-ALL), CD30 for lymphomas, or CD33 for Acute 
Myelogenous Leukemia (AML) (14-18).   
Despite the promising results of the immunotherapeutic approaches described 
above, alternative therapies should be investigated for scenarios where MHC is altered 
or downregulated, and also for tumors were no specific antigens have been identified. 
While MHC downregulation serves to escape from T cell recognition, it makes target cells 
more susceptible to NK cells. Because NK cells are an important component of the innate 
immune system with the capacity of recognizing and eliminating cancer cells without prior 
sensitization, our laboratory focuses on adoptive NK cell therapy for the treatment of 
pediatric malignancies (19, 20). For adoptive cell therapy NK cells are isolated, 
manipulated ex-vivo to enhance anti-tumor response,  and reinfused to patients (8). The 
potential of NK cells for selectively targeting tumor cells, without affecting healthy cells, 
can decrease the risk of complications later in life, making them a promising therapy for 
pediatric cancer patients. 
To evaluate the efficiency of new therapeutic options against pediatric 
cancers the Children’s Oncology Group (COG) has developed the Pediatric Pre-
clinical Testing Program (PPTP) in-vitro panel. This is a panel of over 20 cell lines 
which includes 6 different types of pediatric malignancies comprising leukemia, 
lymphoma, brain tumors, Ewing’s family tumors (EWS), neuroblastoma (NB) and 
rhabdomyosarcoma (RMS).  This panel has been now used for the in-vitro testing 
of more than 50 pediatric cancer therapies (21) and will serve as our in-vitro model 
to test adoptive NK cell immunotherapy.  
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Natural Killer Cell Biology and Functions  
NK cells are part of the innate immune system and they comprise 5-15% of our 
peripheral blood lymphocytes (20). They are typically defined as CD56+/CD3- cells with 
the capacity of recognizing tumor cells without prior sensitization (22, 23) . NK cells are 
heterogeneous and their activity is regulated by a series of inhibitory and activating 
receptors which recognize ligands expressed by target cells. The 3 main receptor 
families present on NK cells include: natural cytotoxicity receptors (NCR’s), C-type lectin 
(CD94/NKG2) and killer cell immunoglobulin like receptors (KIRs). NCR’s (NKp30, 
NKp44, NKp46) are all activating receptors. Other important NK cell activating receptors 
such as DNAM1 and NKG2D have been described. C-type lectin and KIR families 
contain both activating and inhibitory variants (22). The major NK cell activating and 
inhibitory receptors and their respective ligands can be found in Table 1 (Adapted from 
Kannan GS, Aquino-Lopez A, Lee DA, Blood Rev 2016) (24). As observed in table 1, 
different KIRs recognize specific MHC class I molecules, therefore for a KIR to send 
inhibitory signals its corresponding MHC-class I molecule should be expressed in the 
target cell.  
Activation of NK cells has been described by the “missing self” hypothesis, which 
states that the presence of major histocompatibility complex (MHC), which is ubiquitously 
expressed among healthy cells, provides NK cells with a “self” signal which is recognized 
by NK cell inhibitory receptors (KIRs and NKG2A) leading to inhibition of NK cell 
activity(25) (Fig 1, top panel). 
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Some tumor cells are known to downregulate MHC in order to avoid T cell attack 
and can also express activating ligands, making them susceptible targets for NK cell 
attack (Fig. 1, middle panel). In tumor cells where both inhibitory and activating ligands 
are present, the balance between activating and inhibitory signals will determine whether 
the NK cell gets activated (Figure 1, bottom panel. The response of an NK cell to a 
particular target will be determined not only by the expression of ligands in the target, but 
also by the combination of receptors expressed on the NK cell.  
Once an NK cell is committed to kill a target cell it can do it through a variety of 
mechanisms including, granule release (degranulation) (26-28), death receptor pathway 
activation (28, 29), and IFNγ release (28). Upon degranulation NK cells release perforin 
and granzyme, which result in pore formation and target cell apoptosis respectively (27, 
Table 1. Major NK cell activating and inhibitory receptors and their ligands  
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28). For death receptor pathway activation, TNF-related apoptosis inducing ligand 
(TRAIL) on NK cells binds death receptors (DR4 and DR5) on target cells inducing their 
apoptosis (28, 29). 
Figure 1. NK cell function is determined by the balance of inhibitory and 
activating signals.  
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Activated NK cells release IFNγ, a cytokine known to induce MHC upregulation 
which allows for enhanced antigen presentation for T cells (28). NK cells can also 
mediate tumor cell death through antibody dependent cell cytotoxicity (ADCC) (30). In 
ADCC the FcγR/ CD16 receptor of NK cells interacts with the Fc portion of antibodies 
coating tumor cells, this interaction leads to granule release and target cell destruction. 
ADCC mediated by NK cells is in part responsible for the beneficial effects of many 
antibodies used for cancer treatment (30, 31).  
Adoptive NK cell Therapy: From Apheresis Product to Ex-vivo Expansion 
Studies in patients with myeloid leukemia receiving stem cell transplant (SCT) 
showed that NK cells are among the first groups of cells to recover after transplant. 
Increased numbers of NK cells at day 30 post-transplant correlated with enhanced graft 
vs leukemia (GVL) effect, and improved survival (32). Since increased number of NK 
cells showed beneficial effects, investigators explored the idea of adoptive NK cell 
therapy as a way to increase NK cell numbers in the transplant setting for improved 
outcomes. Also NK cells have shown promise in non-transplant settings with therapeutic 
potential for multiple human cancers including leukemia (33), carcinomas (34, 35), 
lymphomas (36), and sarcomas (37, 38).  
Apheresis was the initial platform used to obtain NK cells for adoptive therapy. 
However, given that NK cells compose only 5-15% of our peripheral blood lymphocytes 
(20), purification through apheresis resulted in infusion products ranging from 1x107 – 
5x107 cells/kg which could be used as a single dose infusion (33, 35, 39, 40). Limitations 
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on the number of NK cells that could be obtained through apheresis, the expensive cost 
of the process, as well as its invasive nature, resulted in the development of ex-vivo 
expansion platforms that would allow for production of large quantities of NK cells for 
patient infusion. Multiple ex-vivo expansion platforms have been developed using 
cytokines such as IL-15, IL-2 and IL-21 to stimulate NK cell proliferation. Other ex-vivo 
expansion platforms rely on the use of feeder cells such as cells derived from EBV 
lymphoblastoid cells or modified K562 (leukemia) cells. Ex vivo expansion platforms 
published by multiple research groups are summarized on table 2. Overall, these 
expansion platforms reach a range of 5-550 fold expansion for NK cells in a maximum of 
24 days.  
However, our group has developed an NK cell expansion platform that results in 
the highest expansion fold reported in the literature for NK cells, with a 47,967 fold 
expansion after 21 days in culture (41). It relies on the use of K562 feeder cells modified 
to express membrane bound IL-21 (mb-IL21) in addition to 4-1BBL, from now on I will 
refer to these feeder cells as K562 mb-IL21 (41). Briefly in this expansion platform NK 
cells are stimulated weekly with K562-mb-IL21 for up to 3 weeks. NK cells expanded 
K562 mb-IL21 feeder cells, also referred as IL-21 expanded NK cells, are currently used 
in several trials at MD Anderson for leukemia, and also brain tumors (Refer to Table 3).  
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Table 2. NK cell Ex-vivo Expansion Platforms for Adoptive NK cell Therapy 
 
Days in culture Stimulation NK 
Expansion 
Fold 
Reference 
14 days IL-2  5  (42) 
14 days IL-2 or IL-2 + IL-15  5-20  (43) 
13 days Irradiated T & B cells as 
feeder + IL-15 or IL-2 
25-28.5  (44) 
7 days IL-2 + IL-21 or IL-15 + IL-
21 
CD56bright 40-
50  
CD56dim 10  
(45) 
12 days 
irradiated RPMI 8866 cells 
(EBV+ lymphoblastoid B-
cell line) as feeder 
40  (46) 
21 days Irradiated K562 with 
membrane-bound 
interleukin (IL)-15 and 
41BB ligand as feeder 
277  (47) 
24 days Irradiated K562-MICA-4-
1BBL IL-15 as feeder 
550 (48) 
21 days IL-2 + Irradiated K562 with 
Membrane-bound IL-21 
(mbIL21) tCD19, CD64, 
CD86 and 4-1BBL as 
feeder 
47,967 (41) 
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Table 3. Trials at MD Anderson infusing NK cells expanded on K562 mb-IL21 
feeder cells 
 
 
ClinicalTrials.gov 
Identifier 
Disease Study Title Phase/ Primary 
Outcome 
NCT01787474 AML IL-21-Expanded NK 
Cells for Induction of 
Acute Myeloid Leukemia 
(AML) 
Phase I/II- 
Maximum 
Tolerated Dose 
NCT01904136 Leukemia 
Myeloproliferative 
Diseases 
NK Cells to Prevent 
Disease Relapse for 
Patients High Risk 
Myeloid Malignancies 
Phase I/II- 
Maximum 
Tolerated Dose 
NCT01823198 AML  
Myelodysplastic 
Syndromes 
(MDS) 
Natural Killer (NK) Cells 
With HLA Compatible 
Hematopoietic 
Transplantation for High 
Risk Myeloid 
Malignancies 
Phase I/II- 
Maximum 
Tolerated Dose 
NCT02271711 Brain Cancer Fourth Ventricle 
Infusions of Autologous 
Ex Vivo Expanded NK 
Cells in Children With 
Recurrent Posterior 
Fossa Tumors 
Phase I- 
Maximum 
Tolerated Dose 
NCT02280525 Leukemia 
Lymphoma 
Cord Blood Natural Killer 
(NK) Cells in 
Leukemia/Lymphoma 
Phase I- 
Maximum 
Tolerated Dose 
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Prior studies from our lab demonstrated that IL-21 expanded NK cells secrete 
100-fold more IFNγ than primary NK cells (median secretion of 2493 vs. 24 pg/mL) in 
response to targets (41). Similarly memory like-NK cells used by other groups for 
adoptive transfer to AML patients show increased IFNγ secretion when compared to 
control cells (49).  Therefore, to optimize the use of expanded NK cells as adoptive cell 
therapy it is crucial to better understand how IFNγ affects tumor cell ligand expression 
and NK cell mediated lysis.  
IFNγ and its Opposing Effects in Target Cell Sensitivity to NK-mediated Lysis 
The pro-inflamatory cytokine IFNγ is mainly produced by activated CD8+ 
(Cytotoxic T Lymphocytes), CD4+ helper T cells, and NK cells (50). The secretion of 
IFNγ by immune cells, including NK cells, is known to upregulate MHC-class I expression 
on target cells, which allows for enhanced antigen presentation for T cells (28).  However, 
in the context of NK cells, MHC serves as an inhibitory ligand recognized by NK cell 
inhibitory KIRs and NKG2A (51). Studies have shown an inverse correlation between 
MHC-class I expression and NK cell susceptibility (52). IFNγ has been reported to 
increase resistance of B-cell lymphoma, sarcoma, melanoma, B-cell leukemia and T-cell 
leukemia cells to Lymphokine Activated Killer (LAK) cells and NK cells, which has been 
attributed in part to upregulation of MHC-class I (53, 54). A study with primary cutaneous 
melanoma specimens revealed increased HLA expression for melanoma cells in 
proximity to NK cells. This study also revealed that after co-culturing melanoma cells with 
NK cells, the melanoma cells that were not eliminated had increased HLA expression 
and acquired resistance to NK cell mediated lysis (55).   
35 
 
However, IFNγ has also been reported to increase sensitivity of tumor cells to NK 
cell mediated lysis, and this has been attributed to upregulation Intercellular adhesion 
molecule-1 (ICAM-1/CD54) expression on target cells. ICAM-1 is important for the first 
steps in the immune synapse (IS) formation. NK cell adhesion to target cells is mediated 
by Lymphocyte Function Associated Antigen-1 (LFA-1) binding to adhesion molecules 
such as Intercellular adhesion molecule-1 (ICAM-1/CD54) (56). This adhesion is 
essential for the formation of an effective immune synapse (IS), and an efficient target 
cell lysis. LFA-1 engagement by ICAM-1 has also been shown to promote lytic granule 
convergence to the IS which is important for the cytotoxic effect of NK cells (56, 57). A 
study by Naganuma, et al. reported that IFNγ treatment of neuroblastoma cell line CHP-
134 increased its sensitivity to Lymphokine Activated Killer (LAK) cells, and attributed 
this in part to increased ICAM-1 expression and formation of conjugates (58). In addition, 
Wang et al. reported increased NK cell mediated cytolysis for THP-1 cells (AML) after 
IFNγ treatment overnight. They attributed this increase in sensitivity for THP-1 cells to 
increased ICAM-1 expression on tumor cells and enhanced adhesion of NK cells to target 
cells after IFNγ treatment (59).  
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Aim of the study 
Traditional chemotherapy and radiation increase the risk of life threatening 
complications later in life for childhood cancer survivors. Therefore, there is a critical 
need to develop new therapies that will allow us to eradicate the tumor, while decreasing 
morbidity. Adoptive transfer of NK cells, is a promising therapeutic approach for the 
pediatric population. NK cells have the potential of selectively targeting tumor cells and 
this can result in decreased risk of complications later in life. In order to study NK cells 
we isolate and expand NK cells from human donors. Each donor has a very 
heterogeneous pool of NK cells with variability in their receptor expression and their 
potential to kill tumor cells. Therefore, we hypothesize that particular subpopulations of 
NK cells with increased cytotoxic activity against pediatric malignancies can be identified 
and expanded for enhanced cytotoxic activity of the NK cell infusion product. Also, our 
laboratory has shown that mb-IL21 expanded NK cells have high levels of IFNγ secretion 
when compared to primary NK cells. We hypothesize that IFNγ has a variable effect in 
the tumor cell sensitivity to NK-mediated lysis and alters the NK cell receptor-ligand 
interactions for pediatric cancer cells. In order to test these hypotheses we developed 
three specific aims as follows:  
Specific Aim 1: To determine if subpopulations of NK cells with high cytotoxic 
potential can be identified and expanded for enhanced NK cell product efficiency.  
Specific Aim 2: To determine the effect of exogenous IFNγ on NK cell mediated 
lysis of a panel of pediatric cancer cell lines and the mechanism involved.  
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Specific Aim 3: To determine the impact of NK cell secreted IFNγ on tumor NK cell 
ligand expression.  
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CHAPTER II: MATERIALS AND METHODS 
Isolation and Expansion of Human NK cells 
Buffy coats from four anonymized donors were obtained from Gulf Coast Regional 
Blood Center (Houston TX). Exemption and waiver of consent for the research use of 
buffy coat fractions obtained from anonymized donors at Gulf Coast Regional Blood 
Center (Houston, TX) was granted by the Institutional Review Board of the University of 
Texas MD Anderson Cancer Center under protocol PA13-0978. For NK cells obtained 
from patient infusion products, consent for the research use was granted by the 
Institutional Review Board of the University of Texas MD Anderson Cancer Center under 
protocol 2012-0708. NK cells were isolated using the RossetteSep Human NK cell 
enrichment cocktail (Stem Cell Technologies) and expanded as described previously 
using K562 Clone9.mbIL21 as feeder cells for 21 days (41). Expanded NK cells were 
cryopreserved, and subsequently thawed and recovered for 1-2 days prior to their use. 
During recovery NK cells were cultured in NK cell media consisting of RPMI 1640 
(Corning) supplemented with 50 IU/ml recombinant human IL-2 (Proleukin, Novartis 
Vaccines and Diagnostics, Inc), 20% Fetal Bovine Serum (Thermofisher), L-glutamine 
(Gibco), and penicillin/streptomycin (Corning). 
Tumor Cells 
TC-71, NALM-6, and Ramos-RA1 were obtained as kind gifts from colleagues 
(Drs. ES Kleinerman, LJN Cooper, and J Chandra, respectively). Karpas-299 was 
obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ). 
RS4;11, MOLT-4, and CCRF-CEM were obtained from the America Type Culture 
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Collection (ATCC).  The remaining cell lines were obtained from the Children’s Oncology 
Group (COG) Cell Line and Xenograft Repository. Brain tumor cell lines BT-12, SJ-
GBM2, CHLA-266, Ewing sarcoma (EWS) cell lines CHLA-9, CHLA-10, CHLA-258, TC-
71, neuroblastoma (NB) cell lines NB-1643, NB-EBc1, CHLA-90, CHLA-136, 
rhabdomyosarcoma (RMS) cell line RD, and leukemia cell line COG-LL-317 were 
cultured in IMDM (Lonza) supplemented with 20% FBS (Thermofisher), 4mM L-
Glutamine (Gibco), 1X ITS (Lonza) and penicillin/streptomycin (Corning). Lymphoma cell 
lines Karpas-299, Ramos-RA1, leukemia cell lines NALM-6, RS4;11, MOLT-4, CCRF-
CEM, Kasumi-1, and RMS cell lines Rh41, Rh30, were cultured in RPMI 1640 (Corning) 
supplemented with  10% Fetal Bovine Serum (Thermofisher), L-glutamine (Gibco), and 
penicillin/streptomycin (Corning). Cultures were periodically tested to confirm absence of 
Mycoplasma using MycoAlert Mycoplasma Detection Kit (Lonza). Identity was confirmed 
by STR DNA fingerprinting either using the AmpFℓSTR Identifiler kit (Applied Biosystems) 
or the Power Plex 16HS Kit (Promega) according to manufacturer instructions. The STR 
profiles were compared to known fingerprints as published by ATCC or the COGcell STR 
Genotype Database (http://strdb.cogcell.org). STR profiles were last performed on March 
2016 (SJ-GBM2, NB-1643, MOLT-4), October 2015 (RD, Rh-41, Rh30, BT-12, CHLA-
10, NB-EBc1, NALM-6, and Ramos-RA1), or September 2012 (CHLA-266, CHLA-9, 
CHLA-258, TC-71, CHLA-90, CHLA-136, RS4;11, COG-LL-317, CCRF-CEM, Kasumi-1 
and Karpas-299). Banks of STR validated, mycoplasma-free cell lines were 
cryopreserved. Cell lines were kept in culture no longer than 8 passages or 4 weeks prior 
to use. 
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IFNγ treatment of tumor cells 
Cell lines that grow in suspension were seeded at 0.5x106 cells/mL and treated 
with 50ng/mL of IFNγ (Peprotech) for 48 hours. Adherent cells were cultured to a 60-
70% confluence and treated with 50ng/mL of IFNγ (Peprotech) for 48 hours. Untreated 
tumor cells were seeded in parallel. After treatment cells were washed in IFNγ free 
media, and adherent cells were detached with non-enzymatic cell dissociation buffer 
(Gibco) to avoid degradation of cell surface proteins. Treated and untreated cells were 
evaluated for surface expression of NK cell ligands by mass cytometry, and sensitivity to 
NK cell mediated lysis by calcein release assay.   
Cytotoxicity  
The fluorescence based calcein release assay was used to assess cytotoxicity, 
as previously described (41, 60). Adherent cells were detached with non-enzymatic cell 
dissociation buffer (Gibco) and cells were filtered by using a 70ɥm cell strainer (Corning) 
to obtain a single cell suspension. Target cells were labeled with 5 ɥg/mL of calcein-AM 
(Sigma-Aldrich) for 1 hour at 37oC. NK cells were co-cultured with target cells at different 
effector to target (E:T) ratios (10:1, 5:1, 2.5:1, 1.25:1, 0.6:1 and 0.3:1) for 4 hours at 37oC. 
Supernatant fluorescence was determined at 485 nmExc/530 nmEmm using the 
SpectraMax Plus384 spectrophotometer. For cytotoxic assays with ICAM-1 blocking, NK 
cells were loaded with Fc receptor blocker (Biolegend, 422302) prior to co-culture with 
target cells. Anti-ICAM-1 antibody (Biolegend, 322703) or IgG1 isotype (Biolegend, 
400124) were added to calcein loaded target cells at 10μg/mL for 20 minutes at room 
temperature prior to co-culture with NK cells. 
41 
 
Mass Cytometry 
Antibodies for mass cytometry were labeled with heavy metals using Maxpar-X8 
labeling reagent kits (DVS Sciences) according to manufacturer’s instructions and 
titrated for determination of optimal concentration.  The antibodies and their respective 
heavy metal labeling for tumor cells staining can be found in Table 4. Since NK cell 
receptors may have multiple ligands (e.g., NKG2D binds to MICA, MICB, and ULBP1-5), 
or unknown ligands, chimeric receptor:IgG-Fc fusion proteins were tagged with heavy 
metals and used for identification of ligands on tumor cells. Antibodies used for staining 
of tumor cells and NK cells can be found on tables 4-6. For all cells 1.5 x 106 cells were 
stained for viability with 2.5µM cell ID cisplatin (Fluidigm, 201064) in serum free RPMI 
for 1 minute and washed twice with complete media. Subsequently, surface staining was 
performed as previously described (61). Staining media was prepared by adding 5%FBS 
and 0.1% sodium-azide to PBS.  
During the intracellular staining step of tumor cells, 2 different isotopes of cisplatin 
Pt-194 (Fluidigm, 201194) and Pt-198 (Fluidigm, 201198) were used to barcode 
untreated and IFNγ treated samples, respectively, allowing samples to be combined in a 
single tube, minimizing acquisition time and variability between runs. 
For functional mass cytometry experiments, NK cells from patient infusion 
products were co-cultured with 721.221 target cells at a 2:1 E:T ratio for 3 hours in the 
presence of metal conjugated anti-CD107a and protein transport inhibitor Golgi stop. 
After 3 hours, cells were stained with surface and intracellular staining was performed as 
previously described (61). 
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Data was acquired on a CyTOF instrument (DVS Sciences). Files containing only 
live single cells were exported using FlowJo V10 Software and uploaded into Cytobank 
for further analysis (Figure 2) (62). Heatmaps corresponding to median expression of 
ligands on tumor cells were generated using Cytobank (62).  
 
 
 
 
Table 4. CyTOF Panel for Staining of Cancer Cells 
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 (A) Cells were gated to remove beads from the anlaysis followed by (B) gating for 
single cells and removal of aggregates. (C) Dead cells exclusion. Live, single cells were 
exported as FCS files into Cytobank for de-barcoding (D) of treatment conditions. 
Untreated cells were positive for Pt-194 and IFNγ treated cells were positive for Pt-198. 
(E) Gated populations were analyzed and used for the generation of heat maps based 
on median expression of surface ligands 
 
 
 
Figure 2. Gating Strategy and de-barcoding of untreated and IFN gamma 
treated cancer cells 
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Table 5. CyTOF Panel for Phenotyping of Healthy Donor NK cells through 
Expansion 
 
 
 
45 
 
Table 6. CyTOF Panel for Functional Activity of Patient Infusion Products 
  
(Provided by Jolie Schafer, used with permission) 
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SPADE Clustering analysis  
Clustering analysis of NK cell mass cytometry data was performed using 
spanning-tree progression analysis of density-normalized events (SPADE V3.0) software 
(Peng Qiu, et al., 2011) (63). For figures 6 and 8 live single NK cells were gated 
(CD56+/CD3-) and clustered using the following markers: NKp80, CD56, NKp44, NKp30, 
NKG2A, CD226, CD11a, CD272, TIM-3, CD244, CD357, CD134, CD314/NKG2D, 
CD278, CD226, CD137, CD57, and CD253. For figure 10 live single NK cells were gated 
(CD56+/CD3-) and clustered using the following markers: NKp80, CD56, NKp44, NKp30, 
NKG2A, CD226, CD11a, CD272, TIM3, CD16, CD94, CD357, CD134, CD314, CD278, 
CD223, NKp46, NKG2C, CD62L, CD57 and CD253.  
Conjugation Assay 
The determination of effector conjugation to target cells was performed as 
described by Burshtyn et al, with some minor modifications (64). Briefly, NK cells and 
tumor cells were stained with green dye PKH67-GL (Sigma, MINI67) and red dye PKH26-
GL (Sigma, MINI26), respectively, in 5μM dye at 5x106 cells/mL for 5 minutes at room 
temperature. Dye staining was stopped by adding two volumes of FBS and two volumes 
of complete media. Cells were washed twice with complete media and let rest for at least 
1 hour at 37oC. 105 NK cells were combined with 2x105 tumor cells in 200μL, centrifuged 
at 20g for 1 minute (to initiate contact), and incubated at 37oC for 30 min. Cells were 
resuspended by gentle vortexing, fixed with 200 μL of 4% formaldehyde, and analyzed 
by flow cytometry. For antibody blocking experiments NK cells were pre-incubated with 
5μL of Fc blocker (Biolegend, 422302) for 10 minutes to avoid antibody dependent cell 
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cytotoxicity (ADCC). ICAM-1 was blocked on tumor cells by adding 10μg/mL of anti-
CD54/ICAM-1 clone HCD54 (Biolegend, 322703) for 20 minutes at room temperature.  
Timelapse Imaging in Nanowell Grids 
Timelapse experiments were performed in collaboration with Gabrielle Romain 
and Navin Varadarajan from the University of Houston. Experiment was performed as 
described by Romain et al, 2014 (65). Briefly, NK cells were labeled with PKH67 
membrane dye and tumor cells (NB-1643) were labeled with PKH26 dye. Labeled cells-
were co-cultured at 1:1 E:T ratio on the nanowell array. The chip was then incubated on 
media containing Annexin V-Alexa 647 for detection of cell death. Images were obtained 
every 6 minutes for a total of 6 hours.    
NK Cytokine Secretion Assay 
5x105 tumor cells were seeded in the bottom and top chambers of a 6 transwell 
plate (Fisher Scientific, 0.4μm pore size). 1x106 NK cells (Day 21 expanded) were co-
cultured with tumor cells at the top chamber of experimental wells (2:1 E:T ratio). Addition 
of 50ng/mL of IFNγ, in absence of NK cells or tumor cells at the top chamber, served as 
our positive control. Small pore size allows for transfer of cytokines (i.e. IFNγ) but not NK 
or tumor cells to the bottom chamber. Tumor cells were also seeded in absence of NK 
cells and/or exogenous IFNγ on the top chamber to evaluate baseline expression of 
ligands. After 48 hour incubation at 37oC, tumor cells at the bottom chamber were 
detached with non-enzymatic buffer (Gibco) and stained with anti-MHC-class I-FITC 
(Biolegend, clone W6/32), anti-ICAM-1-PE (Biolegend, clone HA58) and anti-PD-L1-
APC (Biolegend, clone 29E.2A3) for 20 minutes at room temperature. To evaluate the 
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effect of NK-secreted IFNγ we blocked IFNγ in the supernatant by adding 10μg/mL of 
anti-IFNγ (Biolegend, clone B27) to the bottom chamber. Addition of 10μg/mL non-
specific anti-IgG1 antibody (Biolegend, clone MOC-21) served as our Isotype control.  
Statistical Analysis 
Statistics were performed in GraphPad Prism Software. For determination of ∆ in 
% Lysis after IFNγ treatment (Figure 1) we used data from 6 different E:T ratios. For each 
donor we calculated the average difference in lysis after IFNγ treatment (%lysis IFNγ 
treated - %lysis untreated). Significance was determined by using the t-test with a 
hypothetical value of zero for comparison.  
Paired and unpaired t-tests were used across experiments with a p<0.05 for 
significance. Description of specific tests used for each analysis are depicted in the figure 
legends.  
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CHAPTER III: IDENTIFICATION OF NK CELL SUBPOPULATIONS WITH UNIQUE 
PHENOTYPE AND ENHANCED FUNCTION 
Rationale 
To use NK cells for adoptive therapy we isolate and expand them from human 
donors. However, each donor has a very heterogeneous pool of NK cells with variability 
in their receptor expression and their potential to kill tumor cells. Therefore, we 
hypothesize that particular subpopulations of NK cells with increased cytotoxic activity 
against pediatric malignancies can be identified and selected for better NK cell product 
activity against pediatric cancer cells.  
In order to test this hypothesis pediatric tumor cells corresponding to 6 tumor types 
were evaluated for their expression of NK cell ligands. Since NK cell activity is based on 
receptor-ligand interactions, knowledge of the NK cell ligands expressed by tumor cells 
would allow us to determine which tumor cells are potentially susceptible to NK cells, and 
which NK cell subpopulations would have enhanced activity, based on receptor 
expression. Knowledge of which subpopulations would be more active can allow us to 
select them to obtain a product enriched on NK cells with enhanced function.   
Results 
Pediatric Solid Tumor Cells Express High Levels of NK-Activating Ligands 
Using mass cytometry we evaluated the expression of 16 NK cell ligands on 22 
pediatric cancer cell lines. Cell lines were obtained from the PPTP in vitro panel and are 
listed on Table 7. Expression of NK cell ligands was quantified in terms of median level 
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of expression and percent positive cells (Figure 3). Our results show that MHC-class I 
and HLA-E, which are known NK cell inhibitory ligands, are expressed in more than 70% 
of tumor cells for most cell lines, with the exception of Rh41, a RMS cell line with 35% 
cells expressing MHC-class I. However, it is important to consider that the anti-MHC-
class I antibody clone used in this study (W6/32) has been shown to recognize classical 
(HLA-A, HLA-B, HLA-C) and non-classical HLA (HLA-E) (66). When evaluating 
expression of activating ligands on tumor cells we noticed that compared to leukemia cell 
lines, many solid tumor cell lines, including RMS, brain tumor, EWS, and NB show higher 
levels of ligands for activating receptors such as NKG2D, DNAM-1 and the NCRs 
(NKp30, NKp44, NKp46) in terms of median expression, and also percent positive cells 
(Figure 3-4). 
After quantifying the percent of cells with activating ligands for the 6 tumor types, 
statistically significant differences were observed between leukemia cells and solid tumor 
cells (Figure 4). While NKG2D ligands were present on 32% of leukemia cells, they were 
observed on an average of 80% of RMS and 68% of EWS cells (p= 0.014, p= 0.009 
respectively). DNAM-1 ligands on the other hand were observed only on 15% of leukemia 
cells but were on 96% of RMS cells (p<0.0001), 65% of brain tumor cells (p<0.0001), 
95% of EWS cells (p<0.0001) and 56% of NB cells (p=0.026). Ligands for the NCR 
NKp30 were on 35% of the leukemia cells but 76 % of the NB cells (p=0.025).  Ligands 
for another NCR, NKp44 were on 16% of the leukemia cells but on 56 % of the NB cells 
(p=0.042).  These results are important because although adoptive NK cell therapy is 
currently on trials mostly for leukemia, the expression of activating ligands on solid 
tumors suggests that NK cells may be a promising therapy for solid tumors as well. 
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Table 7. Pediatric Pre-clinical Testing Program In-Vitro Panel 
 
 
 
  
Cell line Diagnosis 
RD Rhabdomyosarcoma 
(RMS) 
Embryonal 
Rh41 Alveolar 
Rh30 Alveolar  
BT-12 Brain Tumor ATRT 
SJ-GBM2 Glioblastoma 
multiforme 
CHLA-266 ATRT 
CHLA-9 Ewing’s Family 
Tumors (EWS) 
PNET 
CHLA-10 PNET 
TC-71 Ewings 
NB-1643 Neuroblastoma 
(NB) 
MYCN amplified  
NB-EBc1 N/A 
CHLA-90 N/A 
CHLA-136 MYCN amplified  
NALM-6 Leukemia Pre-B cell ALL 
RS4;11 Pre-B cell ALL 
COG-LL-317 T-cell ALL 
MOLT-4 T-cell ALL 
CCRF-CEM T-cell ALL 
Kasumi-1 AML 
Karpas-299 Lymphoma Anaplastic Large Cell  
Ramos-RA1 Burkitt’s 
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Pediatric cancer cell lines were evaluated by mass cytometry for the baseline expression level of multiple NK cell ligands. The 
evaluated markers and their function can be found at the table above. Left Panel. Median expression level normalized by row 
minimum (obtained by evaluating the arcsinh ratio of the median expression compared to the row minimum). Right Panel. Percent 
positive cells for each given marker (Figure obtained from (67)). 
Figure 3. Expression of NK cell ligands in pediatric cancer cell lines. 
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 RMS (n=3), Brain Tumor (n=3), EWS (n=4), NB (n=4), Leukemia (n=6), Lymphoma 
(n=2). Unpaired T-test, *significant p<0.05 
Figure 4. Quantification of percentage positive cells expressing activating 
ligands, classified by tumor type.  
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Increased Expression of Activating and Inhibitory Receptors on IL-21 Expanded 
NK cells  
Given that pediatric solid tumors showed high levels of NK cell activating ligands 
for receptors such as NKG2D, DNAM-1, NKp30 and NKp44 our goal was to generate a 
product with high levels of these receptors. We first evaluated the expression of these 
receptors on IL-21 expanded cells and compared them to primary NK cells for 4 donors 
using mass cytometry. We observed that the number of cells expressing NKG2D, DNAM-
1, NKp30 and NKp44 for day 21 expanded cells was significantly higher than for primary 
NK cells (Figure 5, Top Panel). Not only was the number of cells higher after expansion, 
but also the mean expression of activating receptors NKG2D, DNAM-1, NKp30 and 
NKp44 was statistically higher for IL-21 expanded cells, when compared to primary cells 
(Figure 5, Bottom Panel).  We also evaluated other molecules associated with activation, 
including OX-40, 4-1BB, Lag-3, ICOS and GITR, and observed increased number of cells 
expressing them, as well as mean expression after expansion (Figure 5). Interestingly, 
we also observed increased number of cells expressing inhibitory receptors including 
KIR’s, NKG2A, BTLA and TIM-3 after expansion (Figure 5, Top Panel). The mean 
expression for these was also significantly higher after expansion, when compared to 
primary NK cells. The expression of markers such as NKp80 and CD57, which have been 
associated to NK cell maturation, is decreased for expanded NK cells when compared 
to primary cells. 
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Presence of multiple NK cell activating and inhibitory receptors was evaluated by 
mass cytometry for primary NK cells and expanded NK cells of 4 anonymous donors. 
Only receptor alterations that were statistically significant are depicted on the figure 
(paired t-test, p<0.05). Top Panel represents percent positive cells. Bottom Panel 
represents Mean expression normalized to Day 0.  
Figure 5. Alterations on NK cell receptor expression for IL-21 expanded NK cells 
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Identification of Unique Subpopulations on IL-21 Expanded NK cells from 
Healthy Donors 
Given that we observed higher levels of NK-activating receptors on the IL-21 
expanded NK cell product, we sought to determine whether particular clusters of NK cells 
were responsible for these overall changes in the product phenotype. We used the 
SPADE algorithm to cluster NK cell subpopulations based on their receptor expression. 
Interestingly, after comparing primary NK cells with day 21 expanded NK cells, we 
observed a number of clusters present after expansion that were absent for primary NK 
cells (Figure 6). These unique subpopulations have high expression of the activating 
receptors NKp30, NKp44, DNAM-1, and NKG2D. In addition, they also express high 
levels of other molecules associated with activation such as CD11a (LFA-1), ICOS, OX40 
and 4-1BB. Inhibitory receptors such as KIRs, NKG2A and TIM-3 were also observed on 
high levels for these subpopulations. After gating for these subpopulations on all 4 donors 
we determined that these unique subpopulations, constituted an average of 41.7% of the 
IL-21 expanded NK cell product after 21 days in expansion (Figure 7). To determine 
whether we could find these populations earlier in the expansion we used the same 
SPADE clustering parameters and analyzed 3 healthy donors, at different time-points 
through the expansion, day 0, day 7, day 14, and day 21 (Figure 8). Our results indicate 
that these unique subpopulations can be identified as early as 1 week into the expansion 
process, with a similar phenotype co-expressing high levels of activating receptors 
NKp30, NKp44, DNAM-1, and NKG2D throughout the expansion. Interestingly, 
quantification of these unique subpopulations reveals that they are more abundant at day 
7 (81%), but their abundance decreases throughout the expansion with decreased 
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frequencies at day 14 (64%) and day 21 (48%) (Figure 9). Next, we sought to determine 
the functionality of these unique subpopulations upon target cell encounter. 
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Figure 6. SPADE Clustering Identifies Unique Subpopulation on Expanded NK 
cells from Healthy Donors 
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Figure 6. SPADE clustering Identifies Unique Subpopulations on Expanded NK 
cells from Healthy Donors. NK cells from 4 donors were evaluated by mass cytometry 
for inhibitory and activating receptor expression. SPADE was used to cluster nodes 
based on NK cell receptor expression. Unique clusters, present on expanded NK cells 
but absent on primary NK cells, are highlighted by black contour. The figure shows 
representative results for 1 donor, but results were replicated across all donors. Blue 
indicates low expression, Red indicates high expression.  
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Figure 7. Quantification of Unique Subpopulations on Expanded NK cells from 
Healthy Donors 
Unique subpopulations, unique to day 21 expanded NK cells, were gated and 
quantified. (n=4 donors) 
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Figure 8. SPADE Clustering Identifies Unique Subpopulations Early in the 
Expansion Process 
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Figure 8. SPADE clustering Identifies Unique Subpopulations Early in the 
Expansion Process. NK cells from 3 donors were evaluated by mass cytometry for 
inhibitory and activating receptor expression. SPADE was used to cluster nodes based 
on NK cell receptor expression. Unique clusters, present on day 7, 14 and 21 expanded 
NK cells but absent on primary NK cells, are highlighted by black contour. The figure 
shows representative results for 1 donor, but results were replicated across all donors. 
Blue indicates low expression, Red indicates high expression.  
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Figure 9. Quantification of Unique Subpopulations throughout Expansion 
Unique subpopulations, unique to day 7, day 14 and day 21 expanded NK cells, were 
gated and quantified. (n=3 donors) 
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Unique Subpopulations Identified in Patient Infusion Products have Increased 
Function upon Target Cell Encounter 
After identifying unique subpopulations co-expressing high levels multiple 
activating receptors on healthy donors we sought to determine whether they could be 
found on patient NK cell infusion products, and evaluated their functionality. We obtained 
NK cell infusion products from 6 leukemia patients enrolled in NCT01904136 trial, these 
consist of day 14 expanded donor NK cells prepared at the Good Manufacturing 
Practices (GMP) facility at MD Anderson Cancer Center for adoptive NK cell therapy 
(Refer to table 3). Data derived from patient infusion samples was obtained as a 
collaboration with Jolie Schafer from MD Anderson Cancer Center. To test the 
functionality of NK cells in the infusion product, we co-cultured them with 721.221 targets, 
a classical NK cell target devoid of MHC. Samples were then stained for the presence 
activating and inhibitory receptors, CD107a to evaluate for degranulation, and 
intracellular IFNγ levels. 
First, we were able to identify on the patient infusion products the unique 
subpopulations previously described (Figure 10). These are highlighted by the black 
contours and were identified by the co-expression of high levels of multiple activating 
receptors including NKp44, NKp30, DNAM-1 and NKG2D. Upon quantification these 
unique subpopulations constituted an average of 29.3% of the patient NK cell infusion 
product (Figure 11). In order to evaluate their functionality we gated for these unique 
subpopulations on all 6 patient infusion products and evaluated their degranulation 
(CD107a) and also their cytokine production (IFNγ) compared to ungated cells and the 
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whole product. As observed in Figure 12A, the highest levels of CD107a and IFNγ 
expression within the infusion product are observed within these unique subpopulations 
(n=6 pooled samples). We quantified CD107a and IFNγ levels on the whole product, the 
gated unique subpopulations and ungated cells (Figure 12B, gating strategy). We 
observed that the %CD107a+ cells was significantly higher in the unique subpopulations 
when compared to the whole product or the ungated cells (p=0.0032, p=0.0010 
respectively) (Figure 12C). Similarly, after quantifying the percent of IFNγ+ cells in the 
unique subpopulations versus the whole product or ungated cells we observed that the 
%IFNγ+ cells was significantly higher in the highlighted unique subpopulations 
(p=0.0015, p=0.0017 respectively) (Figure 10C). Similar results were observed in terms 
of mean expression with significantly higher levels of CD107a and IFNγ in the unique 
supopulations when compared to the whole product and ungated cells (Figure 12C). 
When we looked for the cell populations that were CD107a+/IFNγ+ we observed that 
double positive cells were significantly more frequent in the unique subpopulations, when 
compared to the whole product and the ungated cells (p=0.0020, p=0.0015 
respectively)(Figure 12C).  
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Figure 10. SPADE Clustering Identifies Unique Subpopulations Co-Expressing 
High Levels of Activating Receptors on Patient NK cell Infusion Products 
Day 14 expanded NK cells were obtained from 6 patient infusion products and stained 
for NK cell receptor expression by mass cytometry. Clusters were generated using 
SPADE software, figure represents all 6 donors pooled together in a single SPADE three.  
Blue indicates low expression, Red indicates high expression. (Data derived from patient 
samples obtained as a collaboration with Jolie Schafer from MD Anderson Cancer 
Center, used with permission) 
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Figure 11. Quantification of Unique Subpopulations on Patient NK cell Infusion 
Products 
Subpopulations co-expressing high levels of activating receptors DNAM-1, NKG2D, 
NKp30 and NKp44, were gated and quantified for patient NK cell infusion products. 
(n=6) 
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Figure 12. Subpopulations Co-expressing High Levels of Activating Receptors 
have Increased Functional Marker Expression upon Target Cell Encounter 
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Figure 12. Subpopulations Co-Expressing High Levels of Activating Receptors 
have Increased Functional Marker Expression upon Target Cell Encounter. Patient 
NK cell infusion products (Day 14 expanded) were co-cultured with 721.221 target cells. 
Subpopulations highlighted by black contour correspond to unique subpopulations co-
expressing high levels of activating receptors NKp44, NKp30, NKG2D and DNAM1. (A) 
Levels of degranulation (CD107a) and cytokine secretion (IFNγ) after co-culture with 
target cells were evaluated for the gated unique subpopulations, ungated cells and the 
whole product. SPADE clusters represent all 6 donors pooled together. Blue indicates 
low expression, Red indicates high expression. (B) Gating strategy used to quantify 
functional markers. One representative donor. (C) Quantification of CD107a and IFNγ on 
unique subpopulations in comparison to whole product and ungated cells (n=6). Mean 
expression represents Mean Mass Intensity. Paired t-test, p<0.05 significant. (Data 
derived from patient samples obtained as a collaboration with Jolie Schafer from MD 
Anderson Cancer Center, used with permission) 
 
 
 
 
 
 
70 
 
Subsets with Enhanced Function are comprised within CD56bright Populations  
Our previous data revealed that unique subpopulations co-expressing high levels 
of activating receptors could be identified on patient NK cell infusion products. Moreover, 
we could demonstrate that these population of cells have increased function; however, 
selection based on co-expression of multiple activating receptors would be a complex 
process for clinical translation. Interestingly, our SPADE threes reveal that CD56bright 
cells clustered together with the unique subpopulations with enhanced function (Figures 
8,12), therefore we sought to determine whether gating based on CD56 expression could 
distinguish subpopulations with enhanced function upon target cell encounter, 
independent of their expression of other activating receptors. Our results show that 
CD56bright cells constitute 70% of the IL-21 expanded cells (day 14) (n=6) (Figure 13A). 
We proceeded to evaluate the function of this subpopulation (Figure 13B). In terms of 
the degranulation marker (CD107a), we observed that CD107a+ positive cells were 
significantly more abundant within the CD56bright subset, when compared to the CD56dim 
cells (59% vs 42%, p=0.0014). Mean mass intensity (MMI) indicates that CD107a 
expression levels are significantly higher for CD56bright cells (1.8 fold) when compared to 
CD56dim cells (4.97 vs 2.71, p=0.0103). When IFNγ secretion was evaluated, IFNγ+ cells 
were also more abundant within the CD56bright cells than on CD56dim cells (16% vs 6%, 
p=0.0042). MMI reveals significantly higher IFNγ expression for CD56bright cells (2.2 fold) 
when compared to CD56dim cells (3.4 vs 1.5, p=0.0009). Since CD56bright cells were more 
functional than their CD56dim counterparts, we evaluated them for the surface expression 
of activating receptors (Figure 13C). Expression of NKp30 was significantly higher for 
CD56bright cells (3 fold) when compared to CD56dim cells (106.7 vs 35.4, p=0.0002).  
71 
 
Similarly, NKp44 was significantly higher for CD56bright cells (5.3 fold) when compared to 
CD56dim cells (27.3 vs 5.11, p=0.0002). Expression of the activating receptor DNAM-1 
was significantly higher for CD56bright cells (2.2 fold) when compared to CD56dim cells (59 
vs 26.9, p=0.0001). Finally, the activating receptor NKG2D was significantly higher for 
CD56bright cells (1.9 fold) when compared to CD56dim cells (22.13 vs 11.74, p=0.0009). In 
addition, given that NK cells mediate anti-tumor responses through ADCC, we evaluated 
for the presence of the CD16 (FcγR) receptor which is essential for this function. Our 
results reveal that the CD56bright cells have significantly higher levels of CD16 (4 fold) 
when compared to CD56dim cells (32.6 vs 7.9, p=0.012) (Figure 13C).  
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Figure 13. Functional and Phenotypic Differences between CD56bright and CD56 dim 
Populations on Patient NK Infusion Products 
Patient NK cell infusion products were co-cultured with 721.221 target cells. (A) Gating 
strategy for CD56bright and CD56 dim populations. (B) CD56bright and CD56 dim populations 
were evaluated for levels of degranulation (CD107a) and cytokine secretion (IFNγ). (C) 
Quantification of activating receptor expression (n=6). MMI, Mean Mass Intensity. Paired 
t-test, p<0.05 significant. (Patient samples obtained as a collaboration with Jolie Schafer 
from MD Anderson Cancer Center, used with permission) 
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Discussion 
Tumor cells corresponding to 6 pediatric cancer types were evaluated for their 
expression of NK cell ligands. Although currently most adoptive NK cell therapy trials are 
focused on leukemia, after evaluating NK-ligand expression in multiple tumor types we 
observed that, compared to leukemia cells, many of the solid tumor cell lines had 
significantly higher number of cells expressing ligands for the activating receptors DNAM-
1, NKG2D, NKp30 and NKp44 activating ligands (Figures 3-4).  Given that NK cell activity 
is based on receptor-ligand interactions, the high expression of activating ligands on 
these solid tumor cells including RMS, brain tumor, EWS and NB suggests that NK cells 
could be a promising approach to target them.  
To better target these solid tumor cells we would need an infusion product 
enriched on NK cells expressing the receptors DNAM-1, NKG2D, NKp30 and NKp44. 
After comparing primary NK cells with expanded NK cells from healthy donors we 
observed that the activating receptors DNAM-1, NKG2D, NKp30 and NKp44 were 
present in more than 80% of our day 21 expanded NK cell product (Figure 5). Also our 
expanded NK cells have significantly higher expression of the activating receptors 
DNAM-1, NKG2D, NKp30 and NKp44 compared to primary NK cells (Figure 5).  
Interestingly, we also observed that our expanded NK cells have significantly higher 
levels of inhibitory receptors including KIRs and NKG2A when compared to primary cells 
(Figure 5). 
When we looked closely to our healthy donor expansion product and compared it 
to primary cells, by using SPADE clustering algorithm, we observed that there were 
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subpopulations of NK cells present at IL-21 expanded NK cells that were absent on 
primary NK cells (Figure 6). These unique subpopulations constituted about 81%, 64%, 
and 42-48% of day 7, day 14, and 21 expanded cells, respectively (Figure 7, 9). Unique 
subpopulations co-expressed high levels of the activating receptors DNAM-1, NKG2D, 
NKp44 and NKp30, and also high levels of other molecules associated to NK cell 
activation including CD11a (LFA-1), OX40, ICOS and 4-1BB. Interestingly, some of these 
unique subpopulations also express higher levels of inhibitory receptors such as KIRs 
and NKG2A compared to primary NK cells (Figure 6). 
We sought to determine the functionality of these unique subpopulations by 
exposing expanded NK cells from patient infusion products to target cells. In order to do 
this we evaluated day 14 expanded NK-infusion products for leukemia patients (n=6) 
participating at one of the MD Anderson Trials (NCT01904136). First, we could identify 
the unique subpopulations co-expressing high levels of DNAM-1, NKG2D, NKp44 and 
NKp30 on patient infusion products, and it constituted an average 29% of the infusion 
product (n=6) (Figures 10, 11). After identifying the subpopulations we evaluated their 
functionality upon encounter of target cells (721.221). Our data demonstrates that the 
%CD107a+ and %IFNγ+ cells was significantly higher on the unique subpopulations 
when compared to the rest of the infusion product (Figure 12). Similarly, the mean 
expression level of CD107a and IFNγ was significantly higher on the subpopulations 
when compared to the whole infusion product and the ungated cells (Figure 12). This 
indicates that IL-21 expanded cells contain unique NK cell subpopulations co-expressing 
multiple activating receptors, these populations are absent in primary NK cells, and more 
importantly they have increased function.  
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Isolation of these unique populations, perhaps after 1 week of expansion when they are 
more abundant, would presumably allow us to obtain the populations driving most of the 
cytotoxic effects.  However, selection of NK cells based on co-expression of multiple 
activating receptors would be a complex process for clinical translation. Interestingly, our 
findings indicate that the unique hyperactive populations are comprised within the 
CD56bright component of our product (Figures 12-13). Gating for CD56bright cells reveals 
that these cells have higher expression of multiple activating receptors than their CD56dim 
counterparts. In addition, functional experiments reveal higher levels of CD107a and 
IFNγ for the CD56bright cells, when compared to the CD56dim counterparts, indicating they 
are more functional upon target encounter.  
Overall these results suggest that solid tumors are a potential target for NK cell 
therapy. Also, we observed that the expansion process itself can optimize the NK cell 
product by increasing the expression of activating receptors. Finally, clustering analysis 
revealed unique subpopulations on IL-21 expanded NK cells that were absent in primary 
NK cells. More importantly these newly formed populations co-express high levels of 
activating receptors and have increased function when compared to the rest of NK cell 
product. Selection of this unique populations, which are comprised within the CD56bright 
component of our product, is a potential approach to enhance the efficiency of the infused 
product.  
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CHAPTER IV: IFNγ TREATMENT ALTERS NK CELL LIGAND EXPRESSION AND 
NK CELL MEDIATED LYSIS OF PEDIATRIC CANCER CELLS  
This chapter is in part based upon Aquino-López A, Senyukov VV, Vlasic Z, 
Kleinerman ES, Lee DA: Interferon Gamma Induces Changes in Natural Killer (NK) 
Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer 
Cell Lines. Frontiers in immunology 2017, 8:391.   
Rationale 
Previous data from our laboratory has shown that, compared to primary NK cells, 
IL-21 expanded NK cells secrete 20X more IFNγ (111 vs. 2,493 pg/mL, respectively). 
The literature reports opposing effects of IFNγ on tumor sensitivity to NK cell mediated 
lysis. It has been described that IFNγ causes MHC upregulation, which can result in 
target cell resistance to NK cell mediated lysis (53, 54). However, IFNγ has also been 
reported to increase tumor cell sensitivity to NK cell mediated lysis, which has been 
associated to upregulation of the adhesion molecule ICAM-1 (58, 59). These opposing 
effects reported might be due to the focused nature of the studies, where only particular 
tumor types are evaluated. Therefore, our aim was to determine the effect of exogenous 
IFNγ on NK cell mediated lysis of a panel of pediatric cancer cell lines and the mechanism 
involved.  We determined the effect of IFNγ on the sensitivity of pediatric cancer cells to 
NK-mediated lysis by evaluating 6 different tumor types. We also evaluated how IFNγ 
affected NK-ligand expression and whether this correlated with changes in NK-mediated 
lysis. The effect of IFNγ treatment of tumor cells on NK:target kinetic interactions was 
also evaluated.  
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Results 
IFNγ Has a Variable Impact on Tumor Cell Sensitivity to NK-mediated Lysis 
Tumor cells from the PPTP in-vitro panel were treated with IFNγ to evaluate its 
effect on their sensitivity to NK cell mediated lysis. Several pediatric cancer types were 
assessed, including NB, RMS, EWS, brain tumor, leukemia and lymphoma. All cell lines 
were evaluated with 4 NK cell donors consistent across all cell lines. Our results show 
that 6 cell lines develop resistance to NK cell mediated lysis after IFNγ treatment, these 
include the EWS cell lines CHLA-9 (p=0.0037) and CHLA-10 (p=0.0292), leukemia cell 
lines Molt-4 (p=0.0030) and Kasumi-1 (p=0.0231), NB cell line CHLA-136 (p=0.0065) 
and the lymphoma cell line Ramos-RA1 (p=0.0007) (Figure 14). Although the NB cell line 
NB-EBc1 seems to develop resistance to NK cells after IFNγ treatment, this effect was 
not statistically significant (p=0.0669). For the cell lines where significance was achieved 
we observed a consistent effect across all 4 donors at multiple E:T ratios (Figure 15). We 
also observed that 2 cell lines had a significant increase in sensitivity to NK-mediated 
lysis after being treated with IFNγ. These are the glioblastoma cell line SJ-GBM2 
(p=0.0155), and the NB cell line NB-1643 (p=0.0371) (Figure 11). In addition, we 
observed that the brain tumor cell line BT-12 had an increase in sensitivity to NK-
mediated lysis after IFNγ treatment for 3 of 4 NK cell donors. If only these 3 donors are 
evaluated the increase in sensitivity is significant (p=0.0061). For cell lines were 
increased sensitivity was observed, the effect was also consistent across donors and at 
multiple E:T ratios (Figure 15). We observed no changes in sensitivity after IFNγ 
treatment for the remaining cell lines. If we stratify our data by tumor type, our results 
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show that IFNγ had no effect on sensitivity to NK-mediated lysis for any of the RMS cell 
lines. However, for EWS, leukemia and lymphoma cell lines the effect was variable and 
cell line dependent, with some cell lines showing increased resistance after IFNγ 
treatment, while for other cell lines IFNγ had no effect on sensitivity. For brain tumor cell 
lines, IFNγ treatment resulted in enhanced sensitivity to NK cells or had no effect on NK-
mediated lysis.  Interestingly, for NB cells the effect of IFNγ was completely variable with 
some cell lines showing increased resistance to NK-mediated lysis after IFNγ treatment, 
others showing increased sensitivity, and some showing no effect of IFNγ on their 
sensitivity (Figure 11). We also evaluated whether cell lines with different responses to 
IFNγ had significant differences in their baseline sensitivity to NK cells (Figure 16). 
Baseline NK-sensitivity of tumor cells was not significantly different for tumor cell lines 
with different responses to IFNγ (p=0.3292).  
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NK cell cytotoxic activity towards IFNγ-treated and -untreated cancer cells was evaluated 
using calcein release assays. Changes in lysis (∆% Lysis) of treated compared to 
untreated cancer cells were quantified for each NK cell donor. Each shape represents a 
different NK cell donor (the same four donors were used for all cell lines). Color coding 
corresponds to cell line cancer type. P-values are for probability that ∆% ≠ 0 (t-test). 
Squares with dashed lines indicate cancer cell lines with significant (p ≤ 0.05) changes 
in NK cell mediated lysis after IFNγ treatment.   
Figure 14. Waterfall plot of change in lysis by NK cells after treatment of pediatric 
cancer cell lines with IFNγ 
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NK cell cytotoxic activity towards IFNγ treated (gray) and untreated (black) cancer cells 
was evaluated at 6 different effector to target (E:T) ratios using calcein release assays. 
(A) Cell lines showing decreased lysis (Leukemia (Molt-4, Kasumi-1), EWS (CHLA-9, 
CHLA-10), Lymphoma (Ramos-RA1), and NB (CHLA-136)) (B) Cell lines showing 
increased lysis (brain tumors (BT-12, SJ-GBM2) and NB (NB-1643)) after IFN γ 
treatment. The four NK cell donors are represented for all cell lines, except for BT-12 
with 3 donors represented.  
Figure 15. IFNγ has a variable impact on NK cell-mediated cancer lysis. 
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Cell lines for which IFNγ had an impact on sensitivity to NK-mediated lysis were 
evaluated for their average baseline sensitivity at 2.5:1 E:T ratio (n=4 donors). Color 
coding: black-leukemia, orange- lymphoma, green-NB, red-Brain tumor. Unpaired t-test 
with Welch’s correction, p=0.3292.  
 
 
 
 
 
 
Figure 16. Baseline sensitivity of tumor cell lines classified by IFNγ effect. 
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IFNγ alters surface expression of NK cell ligand expression for pediatric cancer 
cells 
The 22 cell lines from the PPTP in-vitro panel were evaluated for NK-ligand 
expression using mass cytometry. Baseline expression levels of NK-ligands for all 22 cell 
lines were compared to expression levels after IFNγ treatment (Figure 17). After 
evaluating all cell lines for the effect of IFNγ in mean expression we observed that the 
ligands that were most upregulated by IFNγ were CD274/PD-L1, CD54/ICAM-1, HLA-
DR, MHC-class I, CD95/FasR and CD270/HVEM (Figure 17A).  We also evaluated the 
data in terms of median expression changes for each individual cell line after IFNγ 
treatment, and observed that the markers most upregulated were  CD274/PD-L1, 
CD54/ICAM-1, HLA-DR, MHC-class I, CD95/FasR and CD270/HVEM (Figure 17B).  
When grouping cell lines by response to IFNγ we did not observe particular ligands being 
uniquely upregulated in cell lines that responded with significant changes in sensitivity 
after treatment (Figure 17B).  However, when we stratified data by tumor type we 
observed that ligands such as PD-L1 were upregulated by IFNγ for cell lines 
corresponding to solid tumors (RMS, brain, EWS, NB), however they seemed to remain 
unaffected for lymphoma and leukemia cell lines (Figure 18).    We also observed that 
IFNγ mediated ICAM-1 upregulation on brain tumor, EWS, NB and leukemia cells, 
however it was not observed for most RMS and lymphoma cell lines.   HLA-DR 
upregulation by IFNγ was observed for EWS and NB cell lines. In terms of MHC-class I, 
IFNγ mediated upregulation was variable across different tumor types, however we 
observed a consistent upregulation for all NB cell lines. Fas receptor expression (CD95) 
was upregulated by IFNγ for leukemia, lymphoma and NB cells, but was not affected for 
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EWS, RMS and brain tumors. Finally, we observed that some brain tumor, EWS and NB 
cell lines upregulated CD270/HVEM after IFNγ treatment (Figure 18).  Among all the cell 
lines evaluated lymphoma cells were the least responsive to IFNγ treatment in terms of 
ligand expression changes, however only two lymphoma cell lines were evaluated in this 
study. 
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Figure 17. Impact of IFNγ treatment on the surface expression of NK cell ligands for pediatric cancer cell lines. 
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Figure 17. Impact of IFNγ treatment on the surface expression of NK cell ligands for pediatric cancer cell lines. (A) 
Change in expression level (Mean Mass Intensity (MMI)) was determined by quantifying the mean of each parameter at baseline 
and after IFNγ treatment for each cell line. Percent change in MMI after IFNγ treatment was calculated for each cell line and box 
plots were generated for each parameter using data obtained from all 22 cell lines. (B) Fold change in median expression for 
each parameter in all cell lines. Heat corresponds to the fold change in median expression after IFNγ treatment (obtained as the 
arcsinh ratio of median expression for the given markers compared to untreated cell line-Control). Cancer type color coding is 
the same as in Figure 1. Cell lines are arranged according to tumor response to IFNγ, squares with dashed lines indicate cell 
lines with significant changes in NK cell mediated lysis after IFNγ treatment
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Figure 18. Major ligands affected by IFNγ classified by tumor type. 
A B 
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Figure 18. Major ligands affected by IFNγ classified by tumor type.  
 IFNγ induced changes in NK cell ligand expression were evaluated by cancer type. A. Heat corresponds to the fold change in 
median expression after IFNγ treatment (arcsinh ratio of median expression for given markers compared to untreated cell line-
Control). B. Y-axis corresponds to the fold increase in marker median expression after IFNγ treatment, obtained by evaluating 
the arcsinh ratio of median expression for the given marker compared to untreated cell line. 
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IFNγ induced changes in ICAM-1 and MHC-class I correlate with changes in NK 
sensitivity 
After evaluating the effect of IFNγ on tumor cell sensitivity to NK-mediated lysis 
and NK-ligand expression, we wanted to determine whether there were any correlations 
between changes in ligand expression and changes in NK-mediated tumor lysis. To do 
that, we first evaluated the expanded NK cells from our donors for the expression of 
receptors corresponding to PD-L1, ICAM-1 and MHC-class I, the ligands most 
upregulated by IFNγ (Figure 19). Our results showed that PD-1, the receptor for PD-L1 
was expressed on 7% of the expanded NK cell product (n=4) (Figure 19). This suggests 
that changes in PD-L1 expression by IFNγ are unlikely to play a role in our model. In 
contrast the ICAM-1 binding integrin, LFA-1, was expressed in >99% of our expanded 
NK cells. In terms of KIR receptor expression in the expanded NK cell product we 
observed that 83.9% of the cells were KIR2DL2/3+, 97.18% KIR2DL1/2DS5+, and 
89.15% KIR3DL1+. In addition, the inhibitory receptor NKG2A was present in 97% of the 
expanded NK cells. 
Since most of the expanded NK cells expressed receptors for MHC-class I (KIRs 
and NKG2A) and ICAM-1 (LFA-1) we decided to focus on the effect of IFNγ on these 
ligands and whether they correlated with changes in sensitivity to NK-mediated lysis 
(Figure 20).   As stated above, MHC-class I upregulation is associated to NK-inhibition, 
while ICAM-1 upregulation is associated to adhesion, which is important for NK cell 
function. We quantified MHC-class I and ICAM-1 upregulation after IFNγ treatment for 
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the cell lines with altered sensitivity (Figure 20 A,B). The ratio of MHC-class I change 
over the change in ICAM-1 was also evaluated (Figure 20C).     
 
 
 
 
 
 
Expression of PD-1, LFA-1, KIRs and NKG2A on the expanded NK cells was obtained 
by mass cytometry (n=4 donors). 
For all the cell lines that became more resistant after IFNγ treatment we observed 
an increase in MHC-class I expression, which correlates with the increased resistance 
(Figure, 20A). However, for some of the cell lines with increased sensitivity after IFNγ 
treatment we also observed MHC-class I upregulation (Figure 20B). Interestingly, for the 
cell lines with increased sensitivity after IFNγ treatment MHC class-I/ICAM-1 change ratio 
was <1, indicating that upregulation of ICAM-1 exceeded MHC-class I upregulation 
(Figure 20B, 20C). Conversely, for 3 of the 6 cell lines where IFNγ induced resistance 
(Kasumi-1, MOLT-4 and CHLA-136) the MHC class-I/ICAM-1 change ratio was >1, which 
indicates that MHC-class I upregulation exceeded ICAM-1 upregulation (Figure 20A, 
Figure 19. Phenotyping of expanded NK cells 
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20C). Interestingly, ICAM-1 upregulation exceeded MHC-class I upregulation (ratio <1) 
for 3 of the cell lines in which IFNγ treatment resulted in decreased NK cell mediated 
lysis (EWS CHLA-9 and CHLA-10 and lymphoma cell line Ramos-RA1).  
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Figure 20. Effect of IFNγ treatment on ICAM-1 and MHC-class I expression for cancer cell lines with altered sensitivity. 
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Figure 20. Effect of IFNγ treatment on ICAM-1 and MHC-class I expression for cancer cell lines with altered sensitivity. 
The effect of IFNγ on ICAM-1 and MHC-class I expression for cell lines in which IFNγ treatment conferred (A) resistance or (B) 
sensitivity to NK cell mediated lysis. Histograms compare ICAM-1 (left) and MHC class I (right) expression for untreated cancer 
cells (top) and IFN γ treated cells (bottom). Bar graphs represent ICAM-1and MHC class I fold change in median expression after 
IFNγ treatment. (C) Ratio of MHC-class I/ ICAM-1 change after IFNγ treatment for cell lines with altered sensitivity. Fold change 
in median expression after IFNγ treatment for each parameter was quantified and the ratio was calculated. Ratio <1 indicates 
higher ICAM-1 upregulation, ratio >1 indicates higher MHC-class I upregulation after IFNγ treatment.
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IFNγ induced ICAM-1 upregulation increases conjugate formation for cell lines 
with increased sensitivity 
The effect of IFNγ on MHC-class I expression has been already associated to 
target cell resistance to NK-mediated lysis (53, 54), therefore we wanted to investigate 
possible mechanisms for the enhanced sensitivity observed after IFNγ treatment for the 
cell lines SJ-GBM2, NB1643 and BT-12. These cell lines presented with increased 
sensitivity to NK-mediated lysis after IFNγ treatment, despite presence of high levels of 
MHC-class I (Figure 15B, 20B). For these tumors upregulation of the adhesion molecule 
ICAM-1 exceeded MHC-class I upregulation, therefore we decided to determine whether 
IFNγ-mediated ICAM-1 upregulation correlated to increased NK function through 
increased NK:target conjugate formation (Figure 21). We also evaluated NK conjugates 
with Ramos-RA1, a cell line with ICAM-1 upregulation exceeding MHC-class I 
upregulation (ratio <1) for which IFNγ resulted in resistance. We observed IFNγ 
treatment resulted in a significant increase in conjugate formation for BT-12 (p= 0.026) 
and SJ-GBM2 (p=0.011) (Fig 21B). For the cell line NB-1643 although we were not able 
to show statistical significance we saw a trend towards increased conjugate formation 
(p=0.069). In contrast, IFNγ treatment did not increase conjugate formation for Ramos-
RA1. Next, to determine whether the increased conjugate formation after IFNγ treatment 
was ICAM-1 mediated we blocked ICAM-1 on IFNγ treated cells (BT-12, SJ-GBM2 and 
NB1643). ICAM-1 blockade on IFNγ treated tumor cells, with anti-ICAM-1 antibody, 
resulted in a significant decrease in NK:target conjugate formation compared to isotype 
control antibody [BT-12 (p=0.042), SJ-GBM2 (p=0.008) and NB1643 (p=0.041)] (Figure 
21C). 
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(A) y-axis represents fluorescence of labeled target cells, x-axis represents fluorescence 
of labeled NK cells, and Q2 indicates dual fluorescence of NK cells conjugated with target 
cells. (B) Quantification of % NK cells in conjugate with BT-12, SJ-GBM2, NB1643 and 
Ramos-RA1. (C) Quantification of %NK cells in conjugate after ICAM-1 block for IFNγ 
treated BT-12, SJ-GBM2 and NB1643. (n=3 donors, Student’s t-test). 
Figure 21. Conjugation Assay for Cell Lines with Increased Sensitivity after IFNγ 
treatment 
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Blocking of ICAM-1 weakens IFNγ induced increase in sensitivity for particular 
cell lines and donors 
Using NK cells from 4 anonymous donors we showed that the cell lines BT-12, 
SJ-GBM2 and NB-1643 had increased sensitivity after IFNγ treatment. This also 
correlated with higher conjugate formation mediated by ICAM-1. Therefore, we sought 
to determine the effect of ICAM-1 blocking on the NK-mediated lysis of IFNγ treated cells. 
Blocking of ICAM-1 on the IFNγ treated tumor cells resulted in a significant decrease of 
the NK-mediated lysis for brain tumor cells (BT-12) (p=0.0146) (Figure 22). Similarly, 
blocking of ICAM-1 on the IFNγ treated NB-1643 tumor cells resulted in a significant 
decrease of the NK-mediated lysis (p=0.0120) (Figure 22). However, these results 
represent experimental replicates using a single anonymous NK cell donor, for whom 
HLA and KIR typing information is unavailable.  
Pediatric tumor cell lines were previously evaluated in our laboratory to determine their 
HLA expression (Table 8, unpublished). Knowing tumor HLA expression, we typed 
donors and selected them based on the expression of licensed KIRs (KIR2DL3, 
KIR3DL1) corresponding to the tumor MHC molecules. This ensures KIR-MHC 
interactions occur and play a role on the balance. These three selected donors were 
used for subsequent functional experiments.   
Table 8. HLA Typing for Selected Tumor Cells 
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Figure 22. The Effect of ICAM-1 blockade on NK cell mediated lysis for IFNγ 
treated cell lines BT-12 and NB-1643. 
 (Left panel) Evaluation of NK-mediated lysis for untreated and IFNγ treated cell lines 
with one representative anonymous NK donor. (Right panel) Evaluation of the effect of 
ICAM-1 blockade in NK-mediated lysis for IFNγ treated tumor cells.  
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Results for functional experiments using the three selected donors show an 
increased NK-mediated lysis after IFNγ treatment for the brain tumor cell line BT-12. 
Although these results are not statistically significant, the trend goes accordingly with our 
previous results for at least 2 of the donors (Figures 23-24). Similarly, blocking ICAM-1 
on IFNγ treated BT-12 cells resulted in decreased NK-mediated lysis, for 2 of the three 
donors (Figures 23, 24). We also evaluated the glioblastoma cell line, SJ-GBM2 with the 
three selected donors, interestingly we were unable to see increased sensitivity after 
IFNγ treatment, but a slight decrease in sensitivity (not significant) (Figure 23). Blocking 
of ICAM-1 did not affect NK-mediated lysis for IFNγ treated glioblastoma cells (Figure 
23). Finally, when the NB cell line (NB-1643) was evaluated with these three selected 
NK cell donors, IFNγ treatment caused a slight, but significant increase in NK-mediated 
lysis (p=0.03) (Figure 23). However, blocking of ICAM-1 caused a decrease in NK-
mediated lysis for only one of the three donors (Figures 23, 25). 
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Figure 23. The Effect of ICAM-1 blockade on NK cell mediated lysis for IFNγ 
treated cell lines BT-12, NB-1643 and SJ-GBM2. 
NK cell donors known to express licensed KIRs for the MHC molecules expressed by 
the tumor cells were used for these experiments (n=3). Top Panel. Calcein release 
assays at 5:1 E:T ratio were used to evaluate the effect of IFNγ on NK-mediated tumor 
lysis. Bottom Panel. For IFNγ treated tumor cells, anti-ICAM-1 antibodies were used to 
block ICAM-1, non-specific IgG1 antibodies were used as isotype control. Each graph 
depicts the results for 3 NK cell donors. Paired t-test (p<0.05, significant).  
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Figure 24. The Effect of ICAM-1 blockade on NK cell mediated lysis for IFNγ 
treated cell line BT-12 
NK cell donors known to express licensed KIRs for the MHC molecules expressed by 
the tumor cells were used for these experiments. Top Panel. Calcein release assays at 
5:1 E:T ratio were used to evaluate the effect of IFNγ on NK-mediated tumor lysis. Bottom 
Panel. For IFNγ treated tumor cells, anti-ICAM-1 antibodies were used to block ICAM-1, 
non-specific IgG1 antibodies were used as isotype control. Each graph depicts 
experimental replicates of a single NK cell donor. Unpaired t-test with Welch’s correction 
(p<0.05, significant).  
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Figure 25. The Effect of ICAM-1 blockade on NK cell mediated lysis for IFNγ 
treated cell line NB-1643. 
NK cell donors known to express licensed KIRs for the MHC molecules expressed by 
the tumor cells were used for these experiments. Top Panel. Calcein release assays at 
5:1 E:T ratio were used to evaluate the effect of IFNγ on NK-mediated tumor lysis. 
Bottom Panel. For IFNγ treated tumor cells, anti-ICAM-1 antibodies were used to block 
ICAM-1, non-specific IgG1 antibodies were used as isotype control. Each graph depicts 
experimental replicates of a single NK cell donor. Unpaired t-test with Welch’s correction 
(p<0.05, significant).  
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IFNγ treatment of Neuroblastoma cells Reduces the Time Required for NK cell 
Contact 
To better understand how IFNγ treatment alters the kinetic interactions between 
NK cells and tumor cells we performed Timelapse imaging in nanowell grids (TIMING) 
experiments in collaboration with Gabrielle Romain and the Varadarajan Lab at 
University of Houston. NK cells were co-cultured in nanowells with NB-1643 tumor cells 
at 1:1 E:T ratio. Subsequently NK:tumor interactions in the nanowells were imaged every 
6 minutes for 6 hours. Imaging allowed for quantification of the absolute time for the first 
NK:target contact  (tseek) and also the time from contact to death (tdeath) (Figure 26). 
Annexin V staining was used to evaluate for tumor cell death. When we evaluated time 
from contact to death we observed that treatment of NB-1643 cells with IFNγ did not 
have an impact on tdeath (Figure 27B).  As we can observe in Figure 20B, by 2 hours after 
NK:target contact, 55-60% of the tumor cells were dead for both, IFNγ treated and 
untreated target cells (Figure 27B).  However, after evaluating tseek we observed that 
when NB-1643 tumor cells were treated with IFNγ, the time to elapsed until the first 
NK:target contact was reduced, compared to untreated tumor cells (Figure 27A). As 
depicted in figure 27A, it took at least 2 hours in co-culture for 71.6% of the NK cells to 
establish contact with the untreated NB-1643 tumor cells, but when tumor cells were 
treated with IFNγ, 73.7% of the NK cells had established contact with them by the first 
hour. We also evaluated the cumulative percentage of NK cells that had established 
contact with target cells over time (Figure 28A). As we can observe in Figure 28A for 
50% of the NK cells to establish contact with the untreated NB-1643 cells it took 42 
minutes, however, when the same tumor cells were treated with IFNγ 50% of the NK 
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cells had established contact with them by 12 minutes. Statistical analysis by Two Way 
ANOVA reveals that IFNγ treatment causes a statistically significant increase in the % of 
NK cells in conjugate (p<0.0001).  We also quantified the average tseek for both tumor 
treatment conditions and our results reveal that IFNγ treatment significantly decreases 
the tseek of NB-1643 cells when compared to untreated tumor cells (75 min vs 47 min, 
respectively) (p<0.0001) (Figure 28B).  
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NK cells were stained with green membrane dye and NB-1643 tumor cells were stained 
with red membrane dye. IFNγ treated and untreated tumor cells were evaluated for 
kinetic interactions with NK cells. Annexin V staining was used as an indicator of tumor 
cell apoptosis. (Performed in collaboration with Gabrielle Romain and Navin Varadarajan 
from the University of Houston) 
Figure 26. Timelapse Imaging: Assay Description and Representative Images. 
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Figure 27. Timelapse quantification of tseek and tdeath for NK cells co-cultured with 
untreated and IFN treated NB-1643 
NK cells were co-cultured with IFNγ treated or untreated NB-1643 tumor cells at 1:1 E:T 
ratio for 6 hours. A. Pie charts represent the tseek (absolute time to contact) for NK cells 
that established contact with target cells (NK with untreated target: n=744) (NK with IFNγ 
treated target: n= 625). B. Pie charts represent the tdeath (time from contact to death) for 
tumor cells after NK cell contact. (Performed in collaboration with Gabrielle Romain and 
Navin Varadarajan from the University of Houston)  
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Figure 28. Timelapse imaging for dynamic quantification of NK in conjugates with NB-1643. 
NK cells were co-cultured with IFNγ treated or untreated NB-1643 tumor cells at 1:1 E:T ratio for 6 hours. NK cells that established 
contact with target cells were gated for the analysis (NK with untreated target: n=744) (NK with IFNγ treated target: n= 625). A. 
Y-axis represents the cumulative percentage NK cells (at a 1:1 E:T) that had established contact with the tumor cell at particular 
time points. Two Way ANOVA revealed that tumor treatment condition (untreated vs IFNγ treated) alters the %NK in conjugate 
(p<0.0001). B. Quantification of the average tseek for NK cells co-cultured with untreated and IFNγ treated NB-1643 cells. Unpaired 
t-test with Welch’s correction reveals significance (p<0.0001). (Performed in collaboration with Gabrielle Romain and Navin 
Varadarajan from the University of Houston)  
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Discussion 
IL-21 expanded NK cells are currently used in clinical trials to target myeloid 
malignancies and also brain tumors (NCT01787474, NCT01904136, NCT01823198, 
NCT02271711). Previous data from our laboratory has shown that these IL-21 expanded 
NK cells secrete 20X more IFNγ than primary NK cells (2,493 vs. 111 pg/mL, 
respectively) (41). In a similar manner, memory-like NK cells, which have been used as 
adoptive cell therapy for AML patients, have shown enhanced production of IFNγ when 
compared to control NK cells (49).  IFNγ has been reported to have opposing effects on 
tumor sensitivity to NK cell mediated lysis. It can result in target cell resistance to NK cell 
mediated lysis through MHC upregulation (53, 54). However, other studies have shown 
increased tumor cell sensitivity after IFNγ treatment, which has been linked to ICAM-1 
upregulation (58, 59). Opposing effects reported might be due the focused nature of the 
studies, were only particular tumor types are evaluated. Given that high levels of IFNγ 
are secreted by NK cell infusion products, and IFNγ has been reported to have opposing 
effects on tumor sensitivity to NK-therapy, we sought to determine the effect of IFNγ on 
NK cell interactions with tumor cells derived from multiple pediatric tumor types. 
A broad selection of 22 pediatric tumor cell lines, including 6 different tumor types, 
were evaluated for the effect of IFNγ on their sensitivity to NK-mediated lysis. Sensitivity 
was evaluated using IL-21 expanded NK cells from 4 independent donors, consistent 
through all 22 cell lines. Our results demonstrate that IFNγ has a variable effect on tumor 
cell sensitivity to NK-mediated lysis. Six of the cell lines evaluated, including leukemia, 
EWS, lymphoma and NB cells, showed a significant decrease in NK-mediated lysis after 
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IFNγ treatment. In contrast, for 3 cell lines including NB and brain tumor cells, IFNγ 
treatment resulted in a significant increase in sensitivity to NK-mediated lysis. The 
remaining 13 cell lines did not show a statistically significant effect of IFNγ on NK-
mediated lysis, although some show trends that could be significant with additional donor 
replicates.  When evaluated by tumor type we observed that IFNγ had no impact on NK-
mediated lysis of RMS cell lines.  However, for EWS, leukemia and lymphoma cell lines 
IFNγ treatment resulted in increased resistance or no effect on sensitivity. For brain 
tumor cell lines, IFNγ treatment had no effect or resulted in enhanced sensitivity to NK-
mediated lysis.  While for NB, the IFNγ effect was completely variable, with some cell 
lines showing IFNγ induced increased resistance, increased sensitivity, or no effect on 
their sensitivity (Figure 14). These results suggest that IFNγ effect on tumor NK-mediated 
lysis is variable and cell line dependent.  
To better understand this variability, CyTOF was used to evaluate the effect of 
IFNγ on tumor NK-ligand expression.  First, we observed that, overall, none of the ligands 
evaluated were downregulated by IFNγ. In contrast, ligands such as CD274/PD-L1, 
CD54/ICAM-1, HLA-DR, MHC-class I, CD95/FasR and CD270/HVEM were upregulated 
in various cell lines corresponding to multiple tumor types. These findings are consistent 
with previously published studies, with the exception of CD270/HVEM (58, 59, 68-73) . 
Although HVEM is involved in T cell regulation (74), its role in NK cell biology has not 
been well described, and to our knowledge, no studies have yet reported its regulation 
by IFNγ.   
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Upregulation of MHC-class I, PD-L1 and ICAM-1 have been previously described 
in studies for individual tumor types, however no study had uncovered the variability of 
responses across different pediatric tumor types. Our results demonstrate that PD-L1 is 
upregulated by IFNγ on pediatric solid tumor cells (RMS, EWS, NB and brain tumors), 
however, no effect was observed for most of the pediatric leukemia and lymphoma cell 
lines. In terms of the adhesion molecule ICAM-1 we observed IFNγ mediated 
upregulation on leukemia, NB, EWS and brain tumors, but not for lymphoma and RMS 
cells.  Previous studies have described IFNγ mediated upregulation of ICAM-1 on NB 
and leukemia cells, however, to our knowledge, no studies have demonstrated IFNγ 
mediated ICAM-1 upregulation on EWS cells (58, 59).  
We observed upregulation of HLA-DR by IFNγ on some cell lines corresponding 
to EWS, NB, and brain tumor cells (Figure 15). HLA-DR, an MHC-class II molecule, is 
important for antigen recognition by helper CD4 T cells as well as their stimulation (75). 
Given that HLA-DR upregulation can stimulate other immune cells in the tumor 
microenvironment, it would be interesting to investigate its impact on tumor response to 
NK immunotherapy as well as other immune therapies.  
Our findings also demonstrate IFNγ induced upregulation of CD95, known as 
FasR (Fas receptor), in a small number of cell lines corresponding to NB and leukemia 
(Figure 15). NK cells can express Fas ligand (FasL) and its interaction with FasR can 
result in tumor cell apoptosis (28). The levels of FasL expression on IL-21 expanded NK 
cells were not evaluated for our study, but it would an interesting factor to evaluate in 
further studies.  
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While some ligands were upregulated by IFNγ in just a few cell lines, the ligands 
CD274/PD-L1, CD54/ICAM-1, and MHC-class I were highly upregulated by IFNγ across 
multiple tumor types, therefore we wanted to determine whether changes in tumor lysis 
after IFNγ treatment could be correlated to changes in their expression. The PD-1/PD-
L1 axis is associated to immune cell suppression, therefore we evaluated if PD-L1 
upregulation by IFNγ played a role at our system. After evaluating for PD-1 expression 
on our expanded NK cells we observed that it was expressed only on 7% of the NK cells. 
In addition, changes in PD-L1 expression did not correlate with our changes in sensitivity, 
cell lines such as BT-12, SJ-GBM2 and NB-1643 which became more sensitive, had 
among the highest levels of PD-L1 upregulation by IFNγ (Figure 17B). Therefore, our 
data suggests that PD-L1 upregulation was not playing a role in our model.  
LFA-1, KIRs and NKG2A were expressed in >90% of our IL-21 expanded NK 
cells, therefore we decided to focus on IFNγ mediated changes on their ligands, ICAM-
1 and MHC-class I. For all the cell lines with increased sensitivity after IFNγ treatment, 
we observed that ICAM-1 upregulation exceeded MHC-class I upregulation (MHC class-
I/ICAM-1 change <1).  This suggests that, even in the presence of high levels of MHC-
class I, IFNγ treatment can result in an increase in NK-mediated lysis, possibly due to 
ICAM-1/LFA-1 interaction. For three of the six cell lines that had increased resistance 
after IFNγ treatment we observed upregulation of MHC-class I exceeding ICAM-1 
upregulation (MHC class-I/ICAM-1 change >1). These results suggest a shift of the NK 
cell activity balance towards inhibition due to increased expression of MHC-class I, which 
binds inhibitory receptors.  However, there are three cell lines were IFNγ induced 
resistance despite ICAM-1 upregulation exceeding MHC-class I upregulation (ratio<1). 
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For these cell lines our model would have predicted increased sensitivity after IFNγ 
treatment. These results suggest that although MHC-class I and ICAM-1 changes can 
explain some of the changes in tumor sensitivity to NK-mediated lysis after IFNγ 
treatment, there must be other factors playing a role.  
Brain tumor cell lines (SJ-GBM2, BT-12) and a NB cell line (NB-1643) showed 
increased sensitivity to NK-mediated lysis after IFNγ treatment even in the presence of 
MHC-class I upregulation. For these cells we observed ICAM-1 upregulation exceeding 
MHC-class I upregulation (MHC class-I/ICAM-1 change <1) after IFNγ treatment, 
therefore we wanted to determine whether the increased sensitivity could be correlated 
to increased NK:target conjugate formation mediated by ICAM-1 upregulation. After 
evaluating conjugate formation for SJ-GBM2, BT-12 and NB1643 we observed an 
increase in the %NK cells in conjugate with IFNγ treated tumor cells when compared to 
untreated cells (Figure 21). Blocking of ICAM-1 on the IFNγ treated tumor cells resulted 
in a decrease on the % NK cells in conjugate. Based on these results we can correlate 
the increased sensitivity observed after IFNγ treatment for these cell lines, with an 
increased effector-target conjugation mediated by ICAM-1 upregulation.  
Since we observed an increase in ICAM-1 mediated conjugate formation after 
IFNγ treatment for these three cell lines, we evaluated whether blocking ICAM-1 
decreased tumor lysis after IFNγ treatment. Initial experiments were performed with 
single anonymous donors and revealed that blocking of ICAM-1 significantly decreased 
NK-mediated lysis of IFNγ treated tumor cells (BT-12, NB-1643) (Figure 22). However, 
these experiments were performed with anonymous NK donors, and to ensure KIR-HLA 
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interactions played a role in the balance, HLA and KIR typed donors were necessary. 
For the subsequent functional experiments NK cell donors were selected for their 
expression of inhibitory KIR receptors corresponding to the tumor HLA. For the brain 
tumor cell line BT-12, our results show an increase in NK-mediated lysis after IFNγ 
treatment for two of the three donors. This increase in lysis was weakened by the 
presence of ICAM-1 blocking antibodies for two donors, indicating that at least for these 
2 donors, ICAM-1 mediated increase in conjugate formation is in part responsible for the 
increase in sensitivity observed. For the NB cell line NB-1643, we observed a significant 
increase in NK-mediated lysis after IFNγ treatment, however, blocking of ICAM-1 
resulted in a significant decrease in NK-mediated lysis for only one of the three donors, 
indicating that for this donor, ICAM-1 mediated increase in conjugate formation is in part 
responsible for the increase in sensitivity observed. Our results for the glioblastoma cell 
line SJ-GBM2 were surprising, we observed decrease in NK-mediated lysis after IFNγ 
treatment with our three selected NK donors, and blocking of ICAM-1 did not affect NK-
mediated tumor lysis. Although the results indicate ICAM-1 upregulation plays a role in 
the increased sensitivity after IFNγ, the results are variable between donors. Donor 
variabilities such as cytomegalovirus (CMV) seropositive status and KIR haplotype were 
not considered for donor selection, these can play a role in the donor NK cell receptor 
repertoire and therefore NK cell activation balance.    
To better understand the kinetic interactions between NK cells and IFNγ treated 
tumor cells we performed timelapse imaging experiments in collaboration with the 
Varadarajan lab at the University of Houston. Our results indicate that the tdeath was not 
affected by IFNγ treatment of the tumor cells (Figure 27B). However, the tseek is 
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significantly decreased for IFNγ treated tumor cells when compared to untreated tumor 
cells (Figure 27A, 28). These results go accordingly with our conjugation data which 
showed that IFNγ treatment of NB-1643 cells resulted in increased %NK cells in 
conjugate after 30 minutes in co-culture. These results suggest that differences in NK 
interactions with untreated and IFNγ treated tumor cells occur early, within the first 2 
hours in co-culture.  
Overall our data demonstrates that IFNγ has a variable impact on tumor sensitivity 
to NK-mediated lysis. The effect of IFNγ can be correlated to changes in NK-ligand 
expression. We have identified MHC-class I and ICAM-1 as some of the key molecules 
altered by IFNγ, whose changes can be correlated to changes in tumor sensitivity, 
however they cannot explain all of the effects observed. Our data also suggest that tumor 
exposure to IFNγ can facilitate ICAM-1 upregulation and enhance NK cell conjugate 
formation with brain tumor cells and NB cells, which correlates with enhanced NK cell 
activity.  
As mentioned above, published literature has already linked IFNγ treatment with 
tumor resistance to NK cell mediated lysis, mediated MHC-class I upregulation (53, 54). 
In addition, other studies link IFNγ treatment to increased sensitivity of target cells to NK-
mediated lysis, mediated by ICAM-1 upregulation (58, 59). The contradictory results from 
these studies are possibly due to the analysis of a small number of targets, and the focus 
on particular tumor types. This is, to our knowledge the first study to evaluate the effect 
of IFNγ on NK-mediated lysis and NK-cell ligand expression for a variety of at least six 
pediatric tumor types. Given that IL-21 expanded NK cells, which are used in clinical 
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trials, secrete large amounts of IFNγ (41), the information obtained through this study will 
be valuable to optimize adoptive NK cell immunotherapy as an alternative treatment for 
pediatric cancers. 
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CHAPTER V: DYNAMIC NK-TUMOR INTERACTIONS ALTER NK-LIGAND 
EXPRESSION ON SURROUNDING TUMOR CELLS  
Rationale 
Given that IL-21 expanded NK cells, currently used in multiple clinical trials, 
secrete 20X more IFNγ than primary NK cells, we evaluated the effect of IFNγ on 
NK:tumor interactions, tumor expression of NK-ligands and tumor sensitivity to NK-
mediated lysis (41). In terms of NK-ligand expression, our results demonstrated that 
MHC-class I, ICAM-1 and PD-L1 were among the ligands most upregulated by 
exogenous IFNγ treatment. Although exogenous IFNγ treatment alters tumor ligand 
expression, whether NK cell secreted IFNγ was sufficient to induce similar changes 
remained unknown. Therefore, we sought to determine whether IFNγ secreted by IL-21 
expanded NK cells was capable of inducing changes in ligand expression. We 
hypothesize that similar to our findings in presence of exogenous IFNγ treatment, IFNγ 
secreted by IL-21 expanded NK cells is capable of inducing upregulation of MHC-class 
I, ICAM-1 and PD-L1.  
Results 
NK secreted IFNγ upregulates MHC-class I, PD-L1 and ICAM-1 in-vitro  
Using transwell plates as a tool, we co-cultured on the top chamber NK cells and 
tumor cells at a 2:1 E:T ratio  for 48 hours, tumor cells alone were cultured on the bottom 
chamber. NK interactions with tumor cells on the top chamber allowed their activation 
and cytokine release. The small pore size allowed for passage of cytokines (i.e. IFNγ) to 
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the bottom chamber, allowing us to evaluate the effect of NK cell secreted cytokines on 
NK-ligand expression for tumor cells in the bottom chamber.   By using anti-IFNγ blocking 
antibodies we verified whether changes in ligand expression observed were mediated 
by NK-secreted IFNγ (Figure 29). The three cell lines with increased sensitivity after IFNγ 
treatment (NB-1643, BT-12 and SJ-GBM2) were evaluated for the effect of NK cell 
secreted IFNγ on their ligands expression. 
For the cell line BT-12, derived from an ATRT brain tumor, our results indicate 
that IFNγ secreted by activated NK cells mediates upregulation of MHC-class I, ICAM-1 
and PD-L1 (Figure 30). The second transwell containing tumor cells only was used as 
our baseline expression for all ligands (Figure 29A). The presence of activated NK cell 
supernatant did not significantly impact the percentage of tumor cells expressing MHC-
class I, but resulted in an increase in the mean expression of MHC-class I for tumor cells. 
For brain tumor cells (BT-12) in contact with the supernatant of activated NK cells there 
was a 2.2 fold increase in MHC-class I mean expression, and this effect was abrogated 
in the presence of α-IFNγ antibodies which decreased levels to virtually baseline levels 
(1.2 fold). In terms of ICAM-1 expression, the presence of NK secreted cytokines had an 
impact on the percentage of tumor cells expressing ICAM-1. For BT-12 tumor cells ICAM-
1 expression was observed initially on 0.95% of the cells, however when tumor cells were 
in contact with the supernatant of activated NK cells this number increased to 15.9%.  In 
terms of the mean expression, tumor contact with NK cell secreted cytokines caused a 
2.4 fold increase in ICAM-1 expression, an effect that was abrogated in the presence of 
α-IFNγ antibodies (1.2 fold, 1.32%). 
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  Figure 29. Cytokine Secretion Assay: Evaluation of the Effect of NK-
secreted IFNγ 
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Figure 29. Cytokine Secretion Assay: Evaluation of the Effect of NK-secreted IFNγ 
on Tumor NK-ligand Expression. A. Transwell plate setup. NK + Tumor cells were co-
cultured at the top chamber, 2:1 E:T ratio for 48 hours. Tumor cells on the bottom 
chamber were evaluated for the effect of IFNγ secreted by activated NK cells on their 
NK-ligand expression by flow cytometry. B. Representative Dot plots and gating strategy 
for ICAM-1 expression on NB-1643 tumor cells cultured under different conditions (setup 
as in A).  C. Representative data for NB-1643 visualized as overlaid histograms.  
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BT-12 (ATRT- Brain Tumor) 
 
 
 
NK cells and BT-12 tumor cells were co-cultured at 2:1 E:T ratio for 48 hours. Tumor 
cells in contact with activated NK cells supernatant were evaluated for ligand expression. 
Figure 30. Effect of NK-secreted IFNγ on BT-12 NK-ligand Expression 
119 
 
Finally, we evaluated the effect of NK cell secreted IFNγ on tumor PD-L1 
expression, since this was another of the ligands highly upregulated by IFNγ. Our results 
indicate that for the BT-12 cell line, PD-L1 baseline expression was 18.7%, however in 
the presence of activated NK cells supernatant this number increased to 47.1%. A similar 
trend was observed in terms of mean expression, culturing tumor cells in the presence 
of activated NK cell supernatant increased PD-L1 expression by 2.6 fold. Again this effect 
was abrogated in the presence of α-IFNγ antibodies, which decreased PD-L1 levels to 
nearly baseline levels (1.1 fold, 19%) (Figure 30).  
For the cell line NB-1643, a neuroblastoma, our results indicate that cytokines 
secreted by activated NK cells, particularly IFNγ, mediate upregulation of MHC-class I, 
ICAM-1 and PD-L1 (Figure 31). Similar to what we observed in the brain tumor cells, the 
presence of activated NK cell supernatant did not significantly impact the percentage of 
tumor cells expressing MHC-class I, but resulted in an increase in the mean expression 
of MHC-class I for NB tumor cells. For NB cells (NB-1643) in contact with the supernatant 
of activated NK cells there was a 2.6 fold increase in MHC-class I expression, an effect 
that was abrogated in the presence of α-IFNγ antibodies which decreased levels close 
to baseline levels (1.8 fold). In terms of ICAM-1 expression, initially ICAM-1 was 
expressed on 1.92% of the NB-1643 cells, however when tumor cells were in contact 
with the supernatant of activated NK cells this number increased to 53.2%.  Tumor 
contact with the supernatant of activated NK cells caused a 3.5 fold increase in ICAM-1 
expression, an effect that was abrogated in the presence of α-IFNγ antibodies which 
decreased ICAM-1 to levels close to baseline (1.8 fold, 4.48%). Finally, we evaluated the 
effect of NK cell secreted IFNγ on tumor PD-L1 expression, our results indicate that for  
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NB-1643 (Neuroblastoma) 
NK cells and NB-1643 tumor cells were co-cultured at 2:1 E:T ratio for 48 hours. Tumor 
cells in contact with activated NK cells supernatant were evaluated for ligand expression. 
Figure 31. Effect of NK-secreted IFNγ on NB-1643 NK-ligand Expression 
121 
 
the NB-1643 cell line, PD-L1 baseline expression was 20.6%, however in the presence 
of activated NK cell supernatant this number increased to 67.7%. In terms of mean 
expression, culturing tumor cells in the presence of activated NK cell supernatant 
increased PD-L1 expression by 3.6 folds, an effect that was abrogated in the presence 
of α-IFNγ antibodies, which decreased PD-L1 levels to virtually baseline levels (0.9 fold, 
12%) (Figure 31). 
Finally, we evaluated the glioblastoma cell line SJ-GBM2, our results cnfirmed 
once again that the IFNγ secreted by activated NK cells can mediate upregulation of 
MHC-class I, ICAM-1 and PD-L1 (Figure 32). Similar to what we observed in the previous 
cell lines, BT-12 and NB-1643, the presence of NK secreted cytokines did not have a 
significant effect on the percentage of tumor cells expressing MHC-class I, however we 
observed an increase in the mean expression of MHC-class I. For glioblastoma cells (SJ-
GBM2) in contact with the supernatant of activated NK cells there was a 1.5 fold increase 
in MHC-class I expression. This effect was abrogated in the presence of α-IFNγ 
antibodies which decreased levels to nearly baseline levels (1.1 fold). In terms of ICAM-
1 expression, for SJ-GBM2 tumor cells, the baseline ICAM-1 expression was 15.7%. 
However, when tumor cells were cultured in the supernatant of activated NK cells this 
number increased to 42.3%.  In terms of mean expression there was also a 1.9 fold 
increase in ICAM-1 expression for SJ-GBM2 cells in contact with the supernatant of 
activated NK cells. This effect was abrogated in the presence of α-IFNγ antibodies which 
decreased ICAM-1 levels to the baseline levels (1.1 fold, 18.4%). Finally, we evaluated 
the effect of NK cell secreted IFNγ on tumor PD-L1 expression. Our results indicate that 
for the SJ-GBM2 cell line, PD-L1 baseline expression was 6.6%.  
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SJ-GBM2 (Glioblastoma) 
NK cells and SJ-GBM2 tumor cells were co-cultured at 2:1 E:T ratio for 48 hours. Tumor 
cells in contact with activated NK cells supernatant were evaluated for ligand expression. 
Figure 32. Effect of NK-secreted IFNγ on SJ-GBM2 NK-ligand Expression. 
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By contrast, in the presence of activated NK cell supernatant this number increased to 
10.3%. Culturing tumor cells in the presence of activated NK cell supernatant had a slight 
impact on mean PD-L1 expression causing a 1.3 fold increase compared to baseline. 
This effect that was abrogated in the presence of α-IFNγ antibodies, which decreased 
PD-L1 levels to levels similar to baseline (1 fold, 5.6%) (Figure 25). 
The three cell lines evaluated had an increased sensitivity to NK-mediated lysis 
after exogenous IFNγ treatment and ICAM-1 upregulation exceeding MHC-class I 
upregulation (MHC/ICAM-1 change ratio <1). Therefore we sought to determine whether 
the MHC/ICAM-1 change ratio remained <1 in the presence of NK cell secreted IFNγ by 
calculating the fold change in median expression (Mean Fluorescence Intensity). For the 
brain tumor cell line BT-12, we saw upregulation of both MHC-class I (2.2 fold) and ICAM-
1 (2.4 fold), with an MHC/ICAM-1 change ratio <1.  Similarly for the NB cell line NB-1643, 
we saw upregulation of both MHC-class I (2.6 fold) and ICAM-1 (3.5 fold) with an 
MHC/ICAM-1 change ratio <1. Finally, when we evaluated the glioblastoma cell line SJ-
GBM2 in presence of NK cell secreted IFNγ there was an upregulation of both MHC-
class I (1.5 fold) and ICAM-1 (1.9 fold), leading to an MHC/ICAM-1 change ratio <1. 
Overall, the MHC/ICAM-1 change ratio remained <1 for all cell lines, indicating that NK 
cell secreted IFNγ caused ICAM-1 upregulation exceeding MHC-class I upregulation.  
 
 
 
124 
 
Discussion 
IL-21 expanded NK cells, currently used in multiple clinical trials, secrete 20X 
more IFNγ than primary NK cells (41). In chapter IV we showed that exposing tumor cells 
to exogenous IFNγ can have an impact on their sensitivity to NK-mediated lysis, tumor 
kinetic interactions with NK cells, and tumor expression of NK-ligands. In terms of NK-
ligand expression, our results showed that the ligands most upregulated by exogenous 
IFNγ treatment were MHC-class I, ICAM-1 and PD-L1 (Figure 17). These results 
demonstrate the capacity of exogenous IFNγ of altering tumor ligand expression, 
however, whether NK cell secreted IFNγ could induce similar changes remained 
uncertain. Given that IL-21 expanded NK cells secrete high levels of IFNγ, we sought to 
determine whether this secreted IFNγ was sufficient to induce changes on tumor NK-
ligand expression.  
In this chapter we demonstrate that, similar to what we observed with exogenous 
IFNγ treatment, culturing tumor cells (BT-12, SJ-GBM2 and NB-1643) in presence of 
activated NK cells supernatant can induce MHC-class I, ICAM-1 and PD-L1 upregulation 
(Figure 26). More importantly, we were able to demonstrate that the cytokine responsible 
for the upregulation was IFNγ. While addition of isotype control antibody (IgG1) did not 
have an effect in MHC-class I, ICAM-1 and PD-L1 upregulation, addition of IFNγ blocking 
antibodies weakened upregulation of all three ligands to nearly baseline levels for all 
three cell lines (Figure 33).   
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Figure 33. Summary of Results: Effect of NK-secreted IFNγ on Tumor NK-ligand 
Expression 
Three tumor cell lines were evaluated for NK-ligand expression by flow cytometry, BT-
12 (circle), NB-1643 (square) and SJ-GBM2 (triangle). NK cell donor was consistent for 
all cell lines.  
After exogenous IFNγ treatment, the three cell lines evaluated showed an 
increased sensitivity to NK-mediated lysis and an MHC/ICAM-1 change ratio <1, 
indicating ICAM-1 upregulation exceeded MHC-class upregulation. Changes in MHC-
class I expression and ICAM-1 expression induced by NK cell secreted IFNγ also 
resulted in an MHC/ICAM-1 change ratio <1 for all three cell lines, indicating that NK cell 
secreted IFNγ also induced ICAM-1 upregulation exceeding MHC-class I upregulation 
for these cell lines.  
Overall these results highlight the importance of NK cell secreted pro-
inflammatory cytokines, such as IFNγ, and the effect they have in tumor ligand 
expression. They also uncover the effect NK cells can have in surrounding cells, even in 
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the absence of direct NK:target contact. Given that IL-21 expanded NK cells secrete high 
levels of IFNγ, knowledge of the ligands upregulated by IFNγ is crucial to optimize 
adoptive NK cell therapy for cancer treatment and can be used as a tool to enhance NK 
cell anti-tumor effects.  
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CHAPTER VI: GENERAL DISCUSSION AND FUTURE DIRECTIONS 
General Discussion 
Current therapeutic approaches for pediatric cancer patients include 
chemotherapy and radiation. While these have improved survival rates for ALL and 
Hodgkin’s Lymphoma, there has been little or no progress in terms of survival for 
patients with solid tumors, such as RMS, osteosarcoma, EWS or gliomas in 20 years 
(2). In addition, childhood cancer survivors who receive chemotherapy or radiation, 
have increased risk of complications later in life when compared to their siblings (4). 
Late effects of chemotherapy and radiation can include not only cardiovascular, 
renal, hepatic and gonadal dysfunction, but also the risk of developing secondary 
malignancies (4). Therefore, there is a critical need to develop alternative 
therapeutic approaches for pediatric cancer patients that could eradicate the 
disease, while decreasing the risks for complications later in life.  
Given that NK cells have the capacity of eliminating cancer cells without prior 
sensitization, adoptive NK cell therapy is proposed as an alternative approach for the 
treatment of pediatric cancer patients (19, 20). The potential of NK cells for selectively 
targeting tumor cells can possibly decrease the risks for complications later in life for 
survivors, making them a promising therapy for pediatric cancer. To use NK cells as an 
adoptive cell therapy our approach includes their isolation and ex-vivo expansion. Our 
expansion protocol is based on mb-IL21 K562 feeder cells, and leads to a 47,967 
expansion fold in 21 days (41). These IL-21 expanded NK cells are currently used at 
multiple clinical trials at MD Anderson Cancer Center (Table 3). However, the field of 
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adoptive NK cell therapy is in its early stages and a better understanding of the NK cell 
ligands expressed by tumor cells, as well as the interactions between IL-21 expanded 
NK cells and tumor cells, is required for optimization of NK cell immunotherapy.    
NK cells have a heterogeneous distribution of inhibitory and activating receptors 
between individuals and within the same individual (76). Given that the activity of NK 
cells is dependent on NK cell receptor-ligand interactions, NK cell subpopulations within 
a single donor can have different potential to target malignancies, depending on the 
expression of NK cell ligands by the cancer cells. Through our work we characterized 22 
pediatric cancer cell lines, corresponding to 6 types of pediatric cancer types (RMS, brain 
tumors, EWS, NB, leukemia and lymphoma) for their expression of NK-ligands. In 
addition, we identified NK cell subpopulations on IL-21 expanded NK cells co-expressing 
high levels of multiple activating receptors and with enhanced activity against target cells.  
Furthermore, given that IL-21 expanded NK cells secrete high levels of IFNγ, we 
explored the effect of IFNγ on NK:tumor interactions, tumor sensitivity to NK-mediated 
lysis, and tumor expression of NK-ligands. Our results revealed that IFNγ has a variable 
impact on tumor sensitivity to NK-mediated lysis. For cell lines with enhanced sensitivity 
after IFNγ we observed ICAM-1 upregulation, leading to enhanced conjugate formation. 
Blocking of ICAM-1 weakened this enhanced sensitivity after IFNγ treatment for selected 
cell lines and NK donors. We were also able to show that IFNγ secreted by IL-21 
expanded NK cells was enough to induce changes in tumor expression of NK cell ligands 
such as PD-L1, MHC-class I and ICAM-1. Information of the impact of IFNγ on NK-target 
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interactions and NK-ligand expression by tumors can be used to optimize the efficiency 
of the NK cell infusion product in the clinical practice.  
Further optimization of adoptive NK cell therapy would require for us to consider 
other factors. Generation of a highly cytotoxic product is important, however infusion of 
this product might not be entirely beneficial if the NK cells are not able to migrate to the 
tumor tissue. Chemokines are small chemotactic proteins secreted by tumor cells. Their 
interaction with chemokine receptors on NK cells results in signaling that promotes NK 
cell trafficking and homing (77). Therefore, additional studies should explore NK cell 
chemokine receptor expression in our expanded NK cell product. In addition, 
chemokines secreted by multiple pediatric tumor types should be explored. Knowledge 
of the chemokines secreted by pediatric cancer cells would allow us to predict the 
chemokine receptor profile required on our NK cell product for an efficient NK cell 
migration to the tumor tissue.  
Future Directions 
Selection of CD56 bright NK-cell Subpopulations for the Treatment of Solid 
Tumors 
In Chapter III we demonstrated that, compared to leukemia cells, solid tumor cells 
have higher expression of ligands for NK cell activating receptors, such as DNAM-1, 
NKG2D, NKp30 and NKp44 (Figures 3-4).  Although current adoptive NK cell trails are 
mostly focused on leukemia, our results suggest that NK cell therapy can be a potential 
therapy for the treatment of pediatric solid tumors such as RMS, EWS, and brain tumors. 
Given that solid tumor cells express ligands for the activating receptors DNAM-1, 
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NKG2D, NKp30 and NKp44, a product enriched on cells co-expressing these receptors 
would be ideal to target them.  
SPADE clustering revealed that IL-21 expanded NK cells from healthy donors 
contain unique subpopulations that are absent on primary NK cells. These unique 
populations co-express high levels of multiple activating receptors (NKp30, NKp44, 
DNAM-1 and NKG2D), and their frequency was the highest after 1 week of expansion 
(81%) (Figures 6-9). NK cells from patient infusion products also contained these unique 
subpopulations, and more importantly, we showed that these unique populations have 
enhanced degranulation, and IFNγ production, when compared to the rest of the product 
(Figure 12). These findings suggest that sorting for these hyperactive subpopulations 
after 1 week of expansion might be beneficial, since at this time-point their abundance is 
the highest (81%). However, sorting for populations co-expressing multiple activating 
receptors can be challenging to translate into the clinical practice. Interestingly, our data 
reveals that the unique hyperactive populations are contained within the CD56bright 
component of the expanded infusion product; therefore, enrichment of CD56bright cells is 
a possible approach to isolate cells with increased anti-tumor function at the 1 week time-
point, for further expansion. Selective expansion of these CD56bright hyperactive 
subpopulations could possibly enhance the product’s cytotoxic potential.   
To test the efficiency of this approach we could sort CD56bright and CD56dim 
populations from the 1 week expanded product and perform in-vitro cytotoxicity assays 
to test their activity against solid tumor cells. We would expect to see increased tumor 
lysis for the CD56bright population when compared to the CD56dim. Subsequently, we 
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could expand these populations for an additional week and evaluate them for phenotype 
and anti-tumor activity, by using CyTOF and calcein release assays respectively.  This 
would allow us to determine whether they have phenotypic and/or functional differences. 
We would expect to see increased co-expression of multiple activating receptors in the 
CD56bright sorted cells, as well as increased anti-tumor activity, when compared to 
CD56dim cells.   
This enrichment approach could be translated to the clinical practice by using 
commercially-available purification, stimulation and sorting platforms such as the Miltenyi 
Prodigy. These platforms allow for automated preparation of the product in a closed 
system, keeping samples from contamination. Multiple investigators have already used 
this platform for successful automated preparation of GMP-compliant NK and CAR-T cell 
infusion products (78, 79).  Particularly, Granzin, et. al., proved the feasibility of 
automated NK cell expansions using an expansion protocol that also relies on feeder 
cells, in this case the Epstein-Barr virus transformed lymphoblastoid cell line (EBV-LCL) 
(79). Briefly, NK cell enrichment from peripheral blood mononuclear cells (PBMC’s) was 
performed by CD3 depletion and CD56 enrichment, using Miltenyi’s magnetic sorting 
platform. Subsequently, the product underwent automated expansion using the 
CliniMACS Prodigy, which was programmed for their expansion conditions (79).  
Closed-system manufacturing could be envisioned combining the CliniMACS 
Prodigy technology for NK cell enrichment and expansion, with the MACS-Quant Tyto 
microchip, for fluorescence based cell sorting (80). After 1 week expansion, fluorescence 
based sorting could be used to enrich the CD56bright population from our infusion product. 
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Subsequent expansion of CD56bright populations for 1 additional week could possibly lead 
to a product with enhanced degranulation capacity and CD16 expression, which could 
ultimately improve our product’s cytotoxic potential and capacity for ADCC. Although the 
MACS-Quant Tyto microchip is not yet clinically approved, its’ capacity to sort at low 
pressures minimizes stress to cells, and given that it is a closed system it could be 
integrated into GMP-compliant protocols in the future (80).   
Combination of adoptive NK cell therapy with anti-PD-L1 antibodies for brain 
tumors 
NK cells play an important role in the antitumor effects of antibodies through 
ADCC (81), therefore it is not surprising that multiple current clinical trials explore the 
combination of NK cells and antibodies for the treatment cancer. For example, 
neuroblastoma cells express the tumor associated antigen (TAA) diaganglioside GD2 
(82, 83), therefore several studies are evaluating NK cells and anti-GD2 antibodies for 
the treatment of neuroblastoma. A phase I trial at St. Jude Children’s Hospital is 
evaluating the combination of humanized anti-GD2 (hu14.18 K322A), with NK cells and 
standard chemotherapy (NCT01576692). Similarly, two phase I trials at Memorial Sloan 
Kettering Cancer Center explore the combination of chemotherapy, NK cells and anti-
GD2 antibodies (NCT02650648, NCT00877110). However, all these studies rely on the 
use of HLA-haploidentical NK cells obtained through apheresis from blood related 
donors, therefore NK cell quantities for infusion are limited.  
Previous data from our laboratory has shown that IL-21 expanded NK cells have 
abundant CD16 expression and are capable of mediating ADCC (41). Moreover, 
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combination of our IL-21 expanded NK cells and anti-GD2 has already proven to be 
beneficial on a neuroblastoma pre-clinical model (84). However, given that TAA’s have 
not been identified for all tumor types, it is worth exploring the combination of IL-21 
expanded NK cells with other types of antibodies, including those that target checkpoint 
molecules such as PD-L1.  
The PD-1/PD-L1 axis is involved in tumor immune escape. Binding of PD-1 on T 
cells to its ligands PD-L1 and PD-L2, which can be found on tumor cells, leads to 
inhibition of T-cell activation (8, 85). Our data demonstrates that IFNγ mediates 
upregulation of PD-L1 for solid tumors such as RMS, brain tumors, EWS and NB (Figure 
18). Also, in chapter IV we described that upon tumor cell encounter, IL-21 expanded NK 
cells secrete enough IFNγ to induce upregulation of PD-L1 ligand on surrounding brain 
tumor cells and NB cells (Figures 30-31). Only a minority of the IL-21 expanded cells 
(7%) express the PD-1 receptor on their surface, and upregulation of PD-L1 on NB and 
brain tumor cells did not result in decreased NK-mediated tumor lysis (Figures 14,17), 
therefore these findings suggests that PD-L1 upregulation by IFNγ would not lead to 
inhibition of the IL-21 expanded NK cells. 
The use of anti-PD-L1 antibodies to mediate additional signaling through ADCC 
in combination with IL-21 expanded NK cells would be a unique and promising approach 
to enhance NK cell cytotoxic effects for brain tumors. Initial contact of IL-21 expanded 
NK cells with tumor cells would lead to their activation and IFNγ release, promoting tumor 
PD-L1 upregulation. Subsequently, addition of the anti-PD-L1 antibody can induce NK 
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cell anti-tumor effects through ADCC, and by blocking of PD-L1 on tumor cells, the anti-
tumor effects of T-cells could be enhanced.  
Although there is currently a phase I/II clinical trial at Fuda Cancer Hospital, China, 
exploring the combination of anti-PD-1 (Nivolumab) and NK cell immunotherapy for solid 
tumors; Nivolumab targets PD-1 on T cells, rather than PD-L1 on the target cells. This 
combination therapy would not result in NK-mediated target death by ADCC (86). In 
addition, this study excludes patients under 30 years and also patients with brain 
metastases (NCT02843204).  
We propose the use of anti-PD-L1 antibodies in combination with IL-21 expanded 
NK cells for brain tumors to enhance NK cell cytotoxic anti-tumor effects through ADCC. 
Given that many of the checkpoint antibodies available have been engineered to prevent 
ADCC, we should ensure that the anti-PD-L1 antibody used for this type of study has a 
native Fc region and is able to induce ADCC (86). Avelumab is an anti-PD-L1 antibody 
that functions to reactivate T-cells and may induce ADCC through its native Fc region 
(86). It was recently approved by the FDA for the treatment of Merkel cell carcinoma in 
patients 12 and older, making it an ideal alternative to test our hypothesis (87).   
We could use orthotopic brain tumor models for ATRT and medulloblastoma, 
which have already been established at Dr. Gopalakrishnan laboratory (88). 
Gopalakrishnan’s group demonstrated that after in-vivo locoregional delivery of IL-21 
expanded NK cells to medulloblastoma bearing mice, there is tumor infiltration and NK 
cell persistence even after 3 weeks (88). This data was the pre-clinical evidence that 
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lead to the phase I trial mentioned in chapter I, in which, IL-21 expanded NK cells are 
being infused into the fourth ventricle of patients with brain tumors (NCT02271711).  
Given that ATRT and medulloblastoma orthotopic brain tumor models have already been 
established at Dr. Gopalakrishnan, we could test the combination of IL-21 expanded NK 
cells with anti-PD-L1 antibodies in this model. For these models brain tumor cells 
transduced with firefly luciferase are injected into the brain of NSG mice. This allows for 
tracking of tumor progression by bioluminisence imaging. In addition, tumor infiltration by 
NK cells can be evaluated by CD45 staining of tissue samples through 
immunohistochemistry. For in vivo experiments we would expected to see decreased 
tumor progression when mice are treated with NK cells + anti-PD-L1, compared to the 
mice treated with NK cells only or anti-PD-L1 only. 
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